Document:

<PAGE>

                                                                   Exhibit 10.18

                                SUPPLY AGREEMENT

                                 BY AND BETWEEN

                         OMRIX BIOPHARMACEUTICALS, LTD,
                                TEL AVIV, ISRAEL

                                       AND

                         TALECRIS BIOTHERAPEUTICS, INC.
                          RALEIGH, NORTH CAROLINA, USA

                                  Page 1 of 30

PORTIONS OF THIS EXHIBIT MARKED BY AN *** HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
<PAGE>

TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                            Page
                                                                            ----
<S>                                                                         <C>
SECTION 1 TERM OF AGREEMENT                                                   4
SECTION 2 PURCHASE AND SALE OF CRYO                                           4
   2.1   Volume Requirements                                                  4
   2.2   Forecasts                                                            5
   2.3   Right of First Refusal                                               5
   2.4   Purchase Orders                                                      6
   2.5   Shipments                                                            6
   2.6   Cooperation of the Parties                                           6
   2.7   Meetings                                                             7
SECTION 3 QUALITY AND SPECIFICATIONS                                          7
   3.1   Specifications                                                       7
   3.2   Testing                                                              7
   3.3   Acceptance                                                           7
   3.4   Latent Defects                                                       7
   3.5   Records                                                              8
   3.6   Alternate Facility                                                   8
SECTION 4 PRICE AND PRICE ADJUSTMENT                                          8
   4.1   Price                                                                8
   4.2   Adjustment to Price                                                  8
   4.3   Price Adjustment Calculation                                         8
SECTION 5 BILLING AND PAYMENT                                                 8
   5.1   Payments                                                             8
   5.2   Payment Disputes                                                     9
SECTION 6 REGULATORY REQUIREMENTS                                             9
   6.1   Compliance with Regulations                                          9
   6.2   Audit                                                                9
   6.3   Regulatory Approvals                                                 9
SECTION 7 NONCONFORMING CRYO AND RECALLS                                     10
   7.1   Nonconforming Cryo                                                  10
   7.2   General Requirements                                                10
   7.3   Distribution and Use Records                                        10
   7.4   Adverse Events                                                      10
   7.5   Customer Notification of Adverse Reactions                          10
   7.6   Withdrawals and Recalls                                             11
   7.7   Complaints                                                          11
SECTION 8 FORCE MAJEURE                                                      11
SECTION 9 REPRESENTATIONS AND WARRANTIES AND DISCLAIMER                      11
   9.1   Regulatory Requirements                                             11
   9.2   Debarment                                                           11
   9.3   Compliance                                                          12
   9.4   Intellectual Property                                               12
   9.5   Representation and Warranties                                       12
   9.6   Disclaimer                                                          14
SECTION 10 TERMINATION                                                       14
   10.1  Termination for Cause                                               14
   10.2  Termination for Talecris' Force Majeure                             14
   10.3  Other Termination Provisions                                        15
   10.4  Effect of Termination                                               15
   10.5  Remedies                                                            15
   10.6  Survival                                                            15
</TABLE>

                                  Page 2 of 30

<PAGE>

<TABLE>
<S>                                                                         <C>
SECTION 11 INDEMNIFICATION                                                   15
   11.1  Indemnification: Talecris                                           15
   11.2  Indemnification: Customer                                           16
   11.3  Joint Responsibility                                                16
SECTION 12 CONFIDENTILITY                                                    16
   12.1  Confidentiality Obligations                                         16
   12.2  Exceptions                                                          16
   12.3  Other Confidentiality Agreements                                    16
SECTION 13 INSURANCE                                                         17
SECTION 14 MISCELLANEOUS                                                     17
   14.1  Consent to Assignment                                               17
   14.2  Entire Agreement and Amendments                                     17
   14.3  Notices                                                             17
   14.4  Independent Contractor                                              18
   14.5  Non-Waiver                                                          18
   14.6  Choice of Law                                                       18
   14.7  Captions                                                            18
   14.8  Severability                                                        19
   14.9  Dispute Resolution                                                  19
   14.10 Set Off                                                             20
   14.11 Conflicting Terms                                                   20
</TABLE>

                                  Page 3 of 30
<PAGE>

                                SUPPLY AGREEMENT

THIS SUPPLY AGREEMENT (this "AGREEMENT") is entered into as of September, 2006
(the "EFFECTIVE DATE"), by and between Talecris Biotherapeutics, Inc., with
offices at 4101 Research Commons, 79 T. W. Alexander Drive, Research Triangle
Park, North Carolina 27709 ("TALECRIS") and Omrix Biopharmaceutical, Ltd., an
Israeli company, with its principal place of business located at MDA Blood
Center, Tel Hashomer Hospital, Tel Aviv 52621 Israel ("CUSTOMER"). Customer and
Talecris are the ("PARTIES").

WITNESSETH

WHEREAS, Talecris is engaged in the manufacture and distribution of
plasma-derived biological products;

WHEREAS, Talecris fractionates plasma into biological products at its Precision
Pharma Services facility and one of the components of the fractionation process
is a licensed intermediate blood fraction known as Cryoprecipitate ("CRYO");

WHEREAS, Customer is in the business of producing and selling fibrin sealant
products (the "Products");

WHEREAS, Customer desires to purchase from Talecris Cryo derived from plasma
fractionated at the Precision Pharma Services, Inc.'s ("Precision Pharma
Services") facility located in Melville, New York (the "Precision Pharma
Services Facility") to be qualified with various Regulatory Authorities (as
defined herein) for use in the manufacture and development of the Products; and

WHEREAS, Customer and Talecris wish to set forth their mutual agreements and
understandings regarding the sale by Talecris and the purchase by Customer of
the Cryo hereunder.

NOW, THEREFORE, for and in consideration of the premises and the mutual
covenants contained herein, and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties hereto do
hereby agree as follows:

                           SECTION 1 TERM OF AGREEMENT

This Agreement shall have an initial term commencing on the Effective Date and
ending on December 31, 2007 ("Initial Term"), unless earlier terminated as
provided in Section 10 or otherwise in this Agreement. In the event that (i)
Customer obtains US FDA approval for use of the Cryo in the Products or Customer
is prepared to assume the Required Quantity obligations of Exhibit A without
such approval and (ii) Talecris has broadly implemented HAV testing on source
plasma during this time period (the occurrence of the fulfillment of the
conditions of clauses (i) and (ii), will initiate the "Commencement Date"), then
the Initial Term shall be extended by three (3) years from the Commencement
Date. The Initial Term may be renewed for two consecutive two (2) year periods
at the option of Customer. Customer must give Talecris at least one (1) year's
written notice prior to the end of each expiring term of its intent to renew
(each an "EXTENDED TERM", along with the Initial Term, the "TERM").

                      SECTION 2: PURCHASE AND SALE OF CRYO

2.1 Volume Requirements. With respect to each twelve (12) month period during
the Term, effective with issuance of the initial forecast described in Section
2.2, Talecris shall make available to Customer, and Customer shall purchase, the
volumes of Cryo set forth in EXHIBIT A, attached hereto (the "REQUIRED

                                  Page 4 of 30

<PAGE>

QUANTITY"). Such volumes may be adjusted as set forth in Section 2.3 and 2.4.
Upon providing a notice of renewal for an Extended Term in accordance with
Section 1, the Required Quantity for the Extended Term shall not be less than
the Required Quantity set forth in EXHIBIT A. All volumes of Cryo to be sold to
Customer shall be determined after deducting quantities representing
Nonconforming Cryo (as defined in Section 7.1 below).

2.2 Forecasts. Within thirty (30) days of the Commencement Date, Customer shall
provide Talecris with an initial twelve (12) month rolling forecast of
Customer's estimated requirements of Cryo by calendar month. Such forecast shall
be deemed attached and incorporated hereto as EXHIBIT B. Customer shall provide
an updated rolling twelve (12) month forecast on or about the commencement of
each calendar month, in form as set forth in EXHIBIT B. Subject to Sections 2.3
and 2.4, the first six (6) months of each rolling twelve (12) month forecast
shall be a firm binding order (a "BINDING FORECAST"). Talecris agrees to deliver
Cryo in the quantities ordered hereunder within +/- 5% of the requirements of
the Binding Forecast (a "DELIVERY DEVIATION"), on such delivery dates as are
specified in the Purchase Orders issued by Customer pursuant to Section 2.5.
Notwithstanding the above, the Delivery Deviation will not accumulate to more
than 10% over any three (3) month period. The Parties agree and acknowledge
that, only after Customer obtains approval from the FDA for use of the Cryo on
the Products, shall Customer be obligated to purchase the Cryo. To the extent
that the aggregate volume of Cryo purchased by Omrix in any (twelve) 12 month
period after the Commencement Date (each, an "Anniversary Year") does not at
least equal the Required Quantity applicable to such Anniversary Year, Talecris
may, within thirty (30) days of the end of such year, invoice Customer for the
total price attributed to such difference (based on the Price set forth in
Section 4 below) and deliver to Customer the invoiced Cryo in accordance with
Section 2.6. Except as otherwise provided under Section 2.3, forecasts for
volumes exceeding the Required Quantity shall require the prior written approval
of Talecris.

2.2.1 On an annual basis starting within thirty (30) days after the Effective
Date, and at least six (6) months prior to the beginning of each Anniversary
Year, Talecris shall provide Customer with written notice of the total quarterly
volumes of Cryo to be manufactured and made available during the following year
(the "AVAILABLE QUANTITY"). Upon six (6) months prior written notice, Customer
may (i) increase the Required Quantity by an amount up to the Available Quantity
and applicable Purchase Orders shall be adjusted to account for such increase,
or (ii) if prior to the Commencement Date, Customer may issue a Purchase Order
for up to the Available Quantity.

2.3 Right of First Refusal

2.3.1 Fee. Upon payment of one million dollars ($1,000,000), and the five (5)
     subsequent payments on the anniversary of the Effective Date of this
     Agreement of one hundred thousand dollars ($100,000) for the remainder of
     the Term ("ROFR Fee"), Talecris grants Customer a right of first refusal
     ("ROFR") during the Term for additional Cryo as detailed below.

2.3.2 Available Quantity. Within thirty days (30) days prior to the beginning of
     each calendar year Talecris shall provide Customer with written notice of
     the total Cryo not already subject to an existing contractual obligation
     that Talecris expects to manufacture and make available to third parties
     for that upcoming year ("Available Quantity"). The Available Quantity shall
     be updated and communicated in writing to Customer (each an "Update") upon
     the following occurrences: 1) six months from the original forecast for
     that year, and 2) if Talecris intends to provide greater volumes of Cryo to
     third parties than those specified in the last Available Quantity forecast
     or Update submitted to Customer.

2.3.3 Purchase Right. Customer shall have fifteen (15) days upon receipt of the
     Available Quantity or any subsequent Update to purchase all or part of the
     available Cryo at the then

                                  Page 5 of 30

<PAGE>

     current price per kilogram called for in this Agreement. Whatever volumes
     Customer has not elected to purchase Talecris shall be free to dispose of
     in its sole discretion. Any additional Cryo Customer purchases pursuant to
     this ROFR shall be added to Customer's binding forecast and minimum volume
     obligations.

2.3.4 Refund of ROFR Fee. If Talecris does not routinely implement HAV testing
     by December 31, 2007, Talecris shall either a) provide HAV testing for all
     Cryo purchased by Customer at no additional cost to Customer, or b) will
     refund entire ROFR Fee paid by Customer. Furthermore, if (i) If Cryo does
     not receive FDA approval and Customer has not exercised any of its rights
     under the ROFR during the Term, or Talecris makes changes to the batch
     production records or the Specification, as described in Section 3.1, such
     that the Cryo is no longer in compliance with the FDA approval received by
     Customer, and Customer did not receive FDA approval for such batch
     production record or Specification change, (ii) Customer terminates this
     Agreement pursuant to Section 6.2, or (iii) Talecris ceases to manufacture
     Cryo, then Talecris shall pay Customer the pro rata share of the RFR Fee
     equal to the ratio between (A) the period since the Commencement Date and
     the date of termination, and (B) six (6) years.

2.3.5 Exclusion of Cryo. For purposes of clarification, Cryo sent to third party
     toll manufacturers for the benefit of Talecris (i.e., not sold to such
     third parties), are not subject to the ROFR provisions contained herein.

2.4 Purchase Orders. Within thirty (30) days after the Commencement Date,
Customer shall deliver to Talecris a purchase order reflecting the aggregate
Cryo volume in the initial Binding Forecast and with each subsequent forecast
set forth in Section 2.2 above, Customer shall deliver a purchase order
reflecting the aggregate Cryo ordered for the six (6) months of the Binding
Forecast (in each case, a "PURCHASE ORDER"). Each Purchase Order shall specify
the volumes of Cyro ordered and the delivery dates. The Parties shall cooperate
to ensure that the Cryo to be purchased by Customer is ordered in a manner so as
to reasonably allow Talecris to produce such Cryo efficiently, without material
swings in volume over the course of any twelve (12) month period.

2.5 Shipments. Talecris agrees that it shall provide Cryo in conformance with
the delivery schedule provided by Customer based on issued Purchase Orders.
Talecris shall include copies of production and test records with each shipment
as specified in the Specifications (EXHIBIT C). Customer shall be responsible
for making the necessary shipping arrangements. All Cryo purchased and sold
hereunder shall be delivered Ex Works (Precision Pharma Services Facility)
(INCOTERMS 2000). Risk of loss for Ciyo in transit shall lie with Customer. All
financial arrangements for shipping and handling of Cryo shall be the
responsibility of Customer.

2.6 Cooperation of the Parties. Talecris shall inform Customer promptly of any
problems that could reasonably be expected to prevent Talecris from providing
timely deliveries of Cryo and the Parties shall cooperate in resolving such
problems relating to the manufacture and supply of Cryo under this Agreement.
The Parties shall use their commercially reasonable efforts to coordinate
maintenance outages and shut-downs of Customer's facility and Precision Pharma
Services Facility, which coordination could include making temporary changes to
the Binding Forecast. Consistent with Section 6.3 below, Talecris will provide
reasonable support to Customer in response to any questions raised by
"Regulatory Authorities" (i.e., all applicable governmental and regulatory
authorities, including, but not limited to, the FDA, subject to Section 6.1)
regarding the production of Cryo at the Precision Pharma Services Facility. For
purposes of clarification, this Section 2.7 does not diminish or expand the
Parties' respective aggregate obligations over any 12- month period to supply
and purchase Cryo in accordance with the Binding Forecast set forth in

                                  Page 6 of 30

<PAGE>

Section 2.2. If Talecris fails to deliver Cryo in accordance within a delivery
schedule, and is unable to make up the quantity in a rolling three (3) month
period, set forth in a Purchase Order, then for each week of delay beyond such
three (3) month period from the delivery schedule date, the Price for the
undelivered quantity shall be reduced by five percent (5%) per each additional
week of delay.

2.7 Meetings. Unless otherwise mutually agreed, the manufacturing representative
of each Party shall meet (either in person or via conference call) no less than
monthly to discuss the forecasts delivered by Customer pursuant to this
Agreement and other matters relevant to the supply of Cryo hereunder. In
addition, a senior manager of each Party shall meet (either in person or via
conference call) on a quarterly basis to discuss matters relevant to the supply
of Cryo hereunder. At least three (3) business days prior to each meeting, each
Party shall deliver to the other Party a written report regarding the issues to
be discussed at such meeting.

                      SECTION 3 QUALITY AND SPECIFICATIONS

3.1 Specifications. Talecris shall manufacture, process, store, distribute,
test, transport, dispose and otherwise handle Cryo at all times in compliance
with cGMPs (as defined in Section 6.1) and other applicable Regulations (as
defined in Section 6.1 below), the Cryo Specifications and Requirements
(attached hereto as EXHIBIT C and incorporated herein by reference the
"SPECIFICATIONS"), and the SOPs as defined in Sections 6.2. All Cryo shall be
produced only at the Precision Pharma Services Facility. The Specifications
shall be renewed annually, consistent with the Term of this Agreement, with each
such renewal deemed attached hereto as EXHIBIT C and incorporated herein by
reference. In the event of a conflict between the provisions of this Agreement
and the provisions of the Specifications, the provisions of this Agreement shall
prevail. Talecris/Precision shall not make changes to the key process parameters
EXHIBIT D that require prior approval from the FDA or the Specifications without
prior reasonable notice to Customer, which prior notice shall be at least six
(6) months unless otherwise required by a regulatory body. Such notice shall be
sufficiently prior to implementation of the changes so as to allow Customer to
amend its regulatory filings and to purchase additional inventory of Cryo. The
key process parameters in effect at the Precision Pharma Services Facility as of
the Effective Date are set forth in EXHIBIT D, attached hereto. If Talecris
changes to EXHIBIT D or the Specifications in such a manner that the Cryo will
no longer be in compliance with the FDA approval received by Customer, then
Customer may upon written notice terminate this Agreement. Additionally, the
Customer agrees to the terms and conditions set forth in the Manufacturing
Agreement, attached hereto as EXHIBIT E.

3.2 Testing. With respect to each shipment of Cryo to be shipped to Customer,
Talecris shall test such Cryo to ensure compliance with the Specifications.
Talecris shall include a certificate of analysis ("COA") as well as all other
documentation described in the Specifications with each shipment of Cryo
disclosing the results of such testing and showing conformance with the
Specifications. Customer shall not perform any additional testing for human
pathogens (Nucleic Acid Testing (NAT) or otherwise) on the Cryo or any
derivatives therefrom without the prior written authorization of Talecris unless
this testing is approved by both parties and is listed in the Specifications.

3.3 Acceptance. Subject to Section 3.4 below, Customer shall have a period of
thirty (30) days from date of its receipt of a shipment of Cryo at Customer's
Israel plant to inspect the delivered Cryo and the accompanying COA (and
documentation described in EXHIBIT C) and reject all or part of the
corresponding shipment of Cryo for nonconformity with the Specifications. If
Customer rejects all or part of such shipment, it shall promptly notify Talecris
and the provisions of Sections 7.1 below shall apply.

                                  Page 7 of 30

<PAGE>

3.4 Latent Defects. If after accepting a shipment of Cryo, Customer subsequently
discovers latent material defects (including without limitation, nonconformance
to the Specifications) not reasonably discoverable during the acceptance period
set forth in Section 3.3, Customer may revoke its acceptance of such shipment of
Cryo by giving written notice and disclosing the nature of any defects to
Talecris as soon as practicable after discovering such defects. In such event,
such Cryo shall be considered a Nonconforming Cryo (as defined in 7.1) to the
extent latent material defects in fact are present and the provisions of Section
7.1 below shall apply.

3.5 Records. Talecris shall maintain production records and other records
required by cGMPs and the Regulations for such time periods referenced thereby.
Talecris shall make such records available to Customer for Customer's inspection
promptly following a written request by Customer.

3.6 Alternative Facility. Talecris represents and warrants that Talecris has no
current plans for closing the Precision Pharma Services Facility during the
Term. If at anytime during the Term, Talecris decides to close the Precision
Pharma Services Facility, then (1) Talecris will provide Customer with twelve
(12) months notice prior to such closing to allow Customer to purchase
additional inventory of Cryo and (2) the parties will negotiate in good faith
terms for transferring the manufacturing of Cryo to an alternative Talecris
facility, which terms shall include allocation of costs necessary for enabling
such alternative facility to manufacture Cryo in accordance with this Agreement,
and Customer's requirements assuming a shared manufacturing arrangement may be
put into place between Omrix and the new manufacturing facility. If the parties
are unable to negotiate an alternative facility, then Customer may terminate
this Agreement upon written notice. Additionally, if Talecris transfers
ownership or control of the Precision Pharma Services Facility, Talecris shall
require the transferee to be bound by the terms of this Agreement, on the same
terms and specifications as applicable to Talecris and Precisions Pharma
Services.

                      SECTION 4 PRICE AND PRICE ADJUSTMENT

4.1 Price. During the Term of this Agreement, Customer shall pay *** per kg of
Cryo for any Cryo purchased hereunder, as adjusted pursuant to Section 4.2 below
("PRICE"). All payments hereunder shall be made in U.S. Dollars. If Cryo from
Precision Pharma Services receives EU regulatory approval, Customer shall have
the option to purchase such Cryo for the European market and the Price for such
Cryo to be sold into the European market shall be *** per kg.

4.2. Adjustment to Price The Price shall be adjusted annually by Talecris on the
first day of each Anniversary Year. Such adjustment to Price (the "PRICE
ADJUSTMENT") shall reflect the change in the CPI-U or increases in acquisition
cost of raw material, which ever is the greater number. For purposes of the
foregoing, "CPI-IF shall mean the unadjusted percentage change for the previous
twelve-month period as published in the Consumer Price Index for all urban
consumers by the U.S. Department of Labor, Bureau of Labor Statistics. For the
avoidance of doubt, the first such Price Adjustment shall become effective at
the end of the first Anniversary Year.

4.3 Price Adjustment Calculations. On the first day of each Anniversary Year or
as soon thereafter as possible, Talecris shall provide for Customer's review and
approval the computation of the Price Adjustment (as determined in accordance
with Section 4.2 above) to be applied in the following Anniversary Year, and the
methodology used in making such computation. Disagreements as to the adjustment
calculation shall be resolved in accordance with Section 14.9.

                                  Page 8 of 30

<PAGE>

                          SECTION 5 BILLING AND PAYMENT

5.1 Payments. Talecris shall deliver to Customer at the address set forth in
Section 14.3 an invoice for shipments of Cryo to Customer as the same is
shipped. Each invoice shall reflect the actual quantity of the Cryo shipped and
the price thereof, as computed in accordance with Section 4. The amount invoiced
by Talecris and payable by Customer during each Binding Forecast period will not
be less than that charge associated with such Binding Forecast, as computed in
accordance with Section 4, unless the actual Cryo delivered is less than the
Binding Forecast due to a Delivery Deviation or Talecris' failure to perform its
obligations under this Agreement, including due to Nonconforming Cryo. Within
thirty (30) days following the receipt of such invoice, Customer shall pay to
Talecris the amount specified therein.

5.2 Payment Disputes. All billing and payment disputes between Customer and
Talecris shall be resolved in accordance with Section 14.9 below.

                        SECTION 6 REGULATORY REQUIREMENTS

6.1 Compliance with Regulations. Talecris shall comply in all material respects
with all applicable laws, requirements, regulations, guidelines, licenses and
directives, including applicable current Good Manufacturing Practices ("CGMPS")
as defined in national and international laws and internationally accepted GMP
compendia including PIC/C and WHO GMP Guide, including all specifications and
procedures for plasma sourcing, plasma testing, and in process testing and all
regulations, specifications, and procedures contained therein, as well as the
contract manufacturing arrangements described in the CBER: "Guidance for
Industry Cooperative Manufacturing Arrangements for Licensed Biologics and
specifically all requirements under section V "Shared Manufacturing
Arrangements" (collectively, "REGULATIONS"). These shall include all applicable
US FDA laws, requirements, regulations, guidelines, licenses and directives,
including applicable cGMPs and FD&C Act (21 USC 301). Talecris commits to
promptly inform Customer of any FDA citation of a deviation from cGMP that may
impact the ability to meet all Specifications of Cryo.

6.2 Audit. Customer shall have the right, on reasonable written advance notice,
and during normal business hours, to inspect and audit the Precision Pharma
Services Facility, and any other Talecris owned facility involved in the
production of Cryo, Standard Operating Procedures (as in effect as of the
Effective Date and amended from time to time upon mutual agreement of the
Parties, and any replacement or successor thereof, "SOPS"), production,
operations, testing, storage and books and records to confirm compliance with
Section 6.1 and Talecris compliance with the terms and conditions of this
Agreement, provided that such inspection or audit does not unreasonably
interfere with the conduct of business of Talecris. Talecris shall use its
commercially reasonable efforts to accommodate any reasonable request made by
Customer to inspect such facility. Talecris shall respond in writing to Customer
regarding any items of noncompliance identified by Customer during such
inspections or audits within fifteen (15) days of Customer's notice thereof and
shall develop a plan, reasonably satisfactory to Customer, to remedy any such
items of noncompliance within sixty (60) days of notice thereof and shall remedy
such items of noncompliance as set forth in such plan, the failure of which
shall entitle Customer to terminate this Agreement in accordance with Section
10.1 hereof. Provided, however, at the election of either party, any dispute
concerning compliance or non-compliance can be referred to arbitration in
accordance with Section 14.9.

6.3 Regulatory Approvals. Talecris/Precision is responsible for maintaining the
FDA license for the cryo intermediate. Customer is solely responsible for
obtaining and maintaining all necessary regulatory approvals from all Regulatory
Authorities necessary to sell and market the Products. Talecris shall, upon
request by Customer, and as reasonably necessary, promptly (in any case, not
longer than thirty (30) days of any such request) provide a plan detailing when
and how all documents or information requested by Customer to support Customer's
efforts to obtain, maintain, or defend the regulatory approvals necessary to
sell the Products in the US will be provided to the Customer.

                                  Page 9 of 30

<PAGE>

Furthermore, the price of the Cryo includes cost associated with fair and
reasonable efforts by Talecris to assist Customer in obtaining US FDA Regulatory
approval. Any information or documents that are not generated as part of
Talecris' normal business practices will be provided at a cost to the Customer.
In the event that the Customer requires additional regulatory support from
Talecris, regulatory support may be provided at an hourly rate of $250 (US
dollars).

                    SECTION 7 NONCONFORMING CRYO AND RECALLS

7.1. Nonconforming Cryo. In the event that Talecris provides Cryo that does not
meet the Regulations or does not conform to the Specifications, or contains
latent defects, or that has not been manufactured, processed, stored,
distributed, tested, transported, disposed of or otherwise handled in accordance
with applicable SOPs, the Specifications, cGMPs and the Regulations
("NONCONFORMING CRYO"), Talecris will at no cost to Customer, and within ninety
(90) days, replace such Nonconforming Cryo with an equivalent amount of
conforming Cryo. If not so replaced, then such Nonconforming Cryo will be
considered a delayed delivery, and the penalties set forth in Section 2.7 will
begin after such ninety (90) day period.

Upon discovery of Nonconforming Cryo, Customer will immediately notify Talecris
of the identification of the Cryo that is rejected by the Customer. The reason
for the rejection will be provided to Talecris. An investigation will be
initiated at Talecris to determine if they concur with the Customer's rejection
and to determine the cause of the Nonconformance. Talecris may request a visit
to the Customer's facility to inspect the Cryo, to sample the Cryo or other
investigational activities as necessary. Talecris must initiate their internal
investigation within fifteen (15) days of notification of Nonconformance from
the Customer.

If Talecris agrees that the material in Nonconforming, Talecris will provide a
written notification to the Customer to destroy the Cryo. The Customer will not
destroy the Cryo without receiving written notification from Talecris.

If Talecris does not agree that the product is Nonconforming and the Customer
and Talecris cannot agree to acceptability a third party arbitrator will
determine the final disposition.

7.2 General Requirements. Customer shall maintain accurate records of the
quantities of Cryo received and the intermediate and final commercial Products
derived from such Cryo.

7.3 Distribution and Use Records. Talecris/ Precision shall maintain and give
Customer access, upon advance notice and at reasonable times, to, production,
donor records and test results with respect to each unit of plasma included in
Cryo delivered to Customer. Such records and results shall be maintained such
that they can rapidly and unequivocally be accounted for and made available to
Customer within fourteen (14) days from the date of request. All such records
will be maintained by Talecris for a time period at or greater than required by
the FDA. Customer shall maintain and give Talecris access, upon advance notice
and at reasonable times, to, records identifying the use of each lot of Cryo and
the Products from which such Cryo was processed. Such records shall be
maintained such that the use of each lot of Cryo can be rapidly and
unequivocally accounted for and made available to Talecris within fourteen (14)
days from the date of request. All such records will be maintained by Customer
for a time period at or greater than required by the FDA. Customer shall assist
Talecris in identifying, tracking and controlling the use of any Cryo identified
in post-donation information as contaminated or otherwise unsuitable for
processing into Products.

7.4 Adverse Events. Customer shall record and investigate all reports of adverse
events in which Products manufactured from Cryo have been implicated. If
Customer determines that a Cryo lot has caused adverse reactions as a result of
such Cryo being manufactured using Cryo, Customer shall immediately

                                  Page 10 of 30

<PAGE>

notify the applicable Regulatory Authorities as required by the Regulations, and
shall promptly notify Talecris. Talecris shall promptly notify Customer of any
adverse event resulting in a market withdrawal or recall involving viral,
bacterial or prion transmission associated with other fractions processed from
the same plasma units as the Cryo or associated with a specific plasma donor
whose plasma was used in the manufacture of Cryo.

7.5 Customer Notification of Adverse Reactions. In the event that during the
course of a preliminary investigation related to a report of any serious adverse
reaction associated with any Customer Products, Customer obtains preliminary
evidence indicating that, according to indications and dosage, the Cryo used in
the manufacture of such commercial Products may have caused such specific
adverse reaction, each customer that received any such commercial Products shall
be notified by Customer and cautioned that any unused containers of the suspect
lots should be withheld from use, pending the outcome of more definitive
investigations and evaluations, with a copy of such notice to the applicable
Regulatory Authority if required. Customer shall promptly provide Talecris with
a copy of such notice. Any and all of the foregoing actions will be executed
with the concurrence of all relevant Regulatory Authority, to the extent
required by law.

7.6 Withdrawals and Recalls. Customer shall make all contacts with the relevant
Regulatory Authority and shall be responsible for coordinating all activities in
connection with any recall or withdrawal of any Products. In the event that
Talecris believes a recall or withdrawal of any Cryo may be necessary or
appropriate, Talecris shall promptly notify Customer in writing. In the event
that Customer initiates a recall or withdrawal of any Products, Customer shall
promptly notify Talecris. If Customer initiates a withdrawal or recall because
the Cryo used in the manufacture of Products caused adverse reactions, then the
cost of such withdrawal or recall shall be reimbursed by Talecris.

7.7 Complaints. Customer and Talecris will cooperate in the reporting,
investigation and evaluation of customer complaints according to
policies/procedures currently in place at Talecris and Omrix.

                             SECTION 8 FORCE MAJEURE

For the purpose of this Agreement, "FORCE MAJEURE" shall mean (i) acts of God,
acts of the public enemy, insurrections, riots, sabotage, strike, work-stoppage
or other labor dispute and natural disasters; (ii) explosions, fires, flood
damage, or loss of electric power not resulting from the negligence of the Party
invoking Force Majeure; (iii) regulatory actions not attributable to any
violation of law on the part of Talecris or Customer, as the case may be and
(iv) in the case of Talecris, events, circumstances, conditions and actions
outside of the control of Talecris that materially and adversely affect the
plasma-derived products industry generally, including, but not limited to,
interruptions of supply of raw plasma due to viral outbreaks, eruption of new
viruses and similar events that are reasonably likely to be subject to action by
any Regulatory Authority; any of (i), (ii), (iii) or (iv) of which, in the case
of Talecris, prevents Talecris from performing its obligations under this
Agreement, or, any of (i), (ii) or (iii) of which, in the case of Customer,
prevents Customer from producing and/or marketing its Products or performing its
obligations under this Agreement. Notwithstanding anything in this Agreement to
the contrary, except Section 11 and Section 12, the party experiencing the Force
Majeure shall be excused from the performance of each of its obligations under
this Agreement upon a Force Majeure, but only to the extent performance of any
such obligation is necessarily prevented, hindered or delayed thereby and only
during the continuance of any such Force Majeure, and shall have no liability
for damages arising from non-performance of any obligation excused by a Force
Majeure. Furthermore, if Customer terminates this Agreement pursuant to Section
10.2, there shall be no further damages arising from any non-performance excused
by a Force Majeure. The Party suffering such Force Majeure shall invoke this
provision by promptly notifying the other Party in writing of the nature and
estimated duration of the suspension period, as well as the extent to which it
will be unable to fulfill its obligations under the Agreement. Each Party shall
be relieved of performance of its obligations under this Agreement during the
time when it is prevented from performing by the failure of the other party to
perform its obligations or because of any event of Force Majeure.

                                  Page 11 of 30

<PAGE>

             SECTION 9 REPRESENTATIONS AND WARRANTIES AND DISCLAIMER

9.1 Regulatory Requirements. Talecris represents and warrants that Talecris has
all applicable government approvals, permits and licenses required in the
performance of its obligations under this Agreement, including the US FDA.

9.2 Debarment. Talecris certifies it will not use in any capacity the services
of any person, including any firm or individual that has been debarred or is
subject to debarment under the Generic Drug Enforcement Act of 1992, amending
the Food, Drug, and Cosmetic Act of 21 U.S.C. 335a (a) or (b). Talecris agrees
to notify Customer promptly in the event any person providing services to
Talecris under the scope of this Agreement is debarred or becomes subject to
debarment.

9.3 Compliance. Talecris represents and warrants that the manufacture,
processing, distribution, testing, transport, storage, disposal and other
handling of Cryo by Talecris until delivery to and processing by Customer shall
(i) conform to applicable SOPs, the Specifications, cGMPs and the Regulations,
and (ii) be free from defects in materials and workmanship and shall not be
adulterated or misbranded within the meaning of the applicable Regulations.

9.4 Intellectual Property. Talecris represents and warrants that the
manufacture, processing, testing, distribution, transport, storage, disposal and
other handling of Cryo does not infringe the intellectual property rights of any
third party and that Talecris validly possesses all licenses to third party
intellectual property necessary or appropriate for the manufacture, processing,
testing, distribution, transport, storage, disposal and other handling of Cryo.

9.5 Representations and Warranties.

     a) Customer hereby represents and warrants to Talecris that:

     (i) Due Organization, Good Standing and Power. Customer is a duly
     organized, validly existing and in good standing under the laws of the
     jurisdiction in which it was organized. Customer has all requisite
     corporate or other power and authority to own or lease and to operate its
     assets and to conduct the business now being conducted by it. Customer is
     duly authorized, qualified or licensed to do business as a foreign
     corporation or other organization in good standing in each of the
     jurisdictions in which its ownership of property or the conduct of its
     business requires such authorization, qualification or licensing, except
     where the failure to have such authorization, qualification or licensing
     could not reasonably be expected to have a material adverse effect on
     Customer or on the consummation of the transactions contemplated hereunder.
     Customer has all requisite corporate power and authority under applicable
     law and its charter documents to enter into this Agreement and to perform
     its obligations hereunder and to consummate the transactions contemplated
     hereby.

     (ii) Authorization and Validity of Agreement. The execution and delivery of
     this Agreement by Customer and the consummation by it of the transactions
     contemplated hereby have been duly authorized and approved by all necessary
     corporate action under applicable law and the relevant charter documents on
     the part of Customer and do not require the approval of the stockholders of
     Customer. This Agreement has been duly executed and delivered by Customer
     and constitutes the legal, valid and binding obligation of Customer
     enforceable against it in accordance with its terms, except as that
     enforceability may be (i) limited by any applicable bankruptcy, insolvency,
     reorganization, moratorium or similar laws affecting the enforcement of
     creditors' rights generally, (ii) subject to general principles of equity
     (regardless of whether that enforceability is considered in a proceeding in
     equity or at law) and (iii) limited

                                  Page 12 of 30

<PAGE>

     by general principles of applicable law regarding the enforceability of
     arbitral awards and judicial decisions.

     (iii) Lack of Conflicts. Neither the execution and delivery of this
     Agreement by Customer or the consummation by it or the transactions
     contemplated hereby, does or will (i) conflict with, or result in the
     breach of any provision of, the charter documents of Customer or (ii)
     violate any applicable law or any permit, order, award, injunction, decree
     or judgment of any governmental authority applicable to or binding upon
     Customer or to which any of its properties or assets is subject.

     (iv) No Consents. The execution, delivery and performance of this Agreement
     by Customer and the consummation of the transactions contemplated by this
     Agreement do not require any governmental approval. No consent (other than
     governmental approvals) will be required to be obtained by Customer for the
     consummation of the transactions contemplated by this Agreement.

(b)  Talecris hereby represents and warrants to Customer that:

     (i)  Due Organization, Good Standing and Power. Talecris is a corporation
          duly organized validly existing and in good standing under the laws of
          the state of Delaware. Talecris has all requisite corporate or other
          power and authority to own or lease and to operate its assets and to
          conduct the business now being conducted by it. Talecris is duly
          authorized, qualified or licensed to do business as a foreign
          corporation or other organization in good standing in each of the
          jurisdictions in which its ownership of property or the conduct of its
          business requires such authorization, qualification or licensing,
          except where the failure to have such authorization, qualification or
          licensing could not reasonably be expected to have a material adverse
          effect on Talecris or on the consummation of the transactions
          contemplated hereunder. Talecris has all requisite corporate power and
          authority under applicable law and its charter documents to enter into
          this Agreement and to perform its obligations hereunder and to
          consummate the transactions contemplated hereby.

     (ii) Authorization and Validity of Agreement. The execution and delivery of
          this Agreement by Talecris and the consummation by it of the
          transactions contemplated hereby have been duly authorized and
          approved by all necessary corporate action under applicable law and
          the relevant charter documents on the part of Talecris and do not
          require the approval of the stockholders of Talecris. This Agreement
          has been duly executed and delivered by Talecris and constitutes the
          legal, valid and binding obligation of Talecris enforceable against it
          in accordance with its terms, except as that enforceability may be (i)
          limited by any applicable bankruptcy, insolvency, reorganization,
          moratorium or similar laws affecting the enforcement of creditors'
          rights generally, (ii) subject to general principles of equity
          (regardless of whether that enforceability is considered in a
          proceeding in equity or at law) and (iii) limited by general
          principles of

                                  Page 13 of 30

<PAGE>

          applicable law regarding the enforceability of arbitral awards and
          judicial decisions.

     (iii) Lack of Conflicts. Neither the execution and delivery of this
          Agreement by Talecris or the consummation by it to the transactions
          contemplated hereby, does or will (i) conflict with, or result in the
          breach of any provision of, the charter documents of Talecris or (ii)
          violate any applicable law or any permit, order, award, injunction,
          decree or judgment of any governmental authority applicable to or
          binding upon Talecris or to which any of its properties or assets is
          subject.

     (iv) No Consents. The execution, delivery and performance of this Agreement
          by Talecris and the consummation of the transactions contemplated by
          this Agreement do not require any governmental approval. No consent
          (other than governmental approvals) will be required to be obtained by
          Talecris for the consummation of the transactions contemplated by this
          Agreement.

9.6 Disclaimer. TALECRIS MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR
IMPLIED OTHER THAN THOSE EXPRESSLY MADE IN THIS AGREEMENT. ALL OTHER WARRANTIES,
EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF
MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, ARE HEREBY DISCLAIMED.

                             SECTION 10: TERMINATION

10.1 Termination for Cause. If either Party commits a substantial violation of
any material provision of this Agreement (which means (i) in the case of
Customer, nonpayment of amounts owing to Talecris in accordance with Section 5.1
or any other material breach of any representation, warranty, covenant or
performance obligations under this Agreement by Customer and (ii) in the case of
Talecris, any material breach of any representation, warranty, covenant or
performance obligation under this Agreement), the other Party may, without
prejudice to any other right or remedy, and after giving the breaching Party
thirty (30) days' written notice of the breach, terminate this Agreement. This
Agreement shall not be so terminated if the breaching Party has cured the
breach, or submitted a plan for curing the breach reasonably acceptable to the
non-breaching Party within thirty (30) days after the non-breaching Party's
notice. If the breaching Party fails to cure the breach as set forth in the
aforementioned plan in accordance with the deadlines set forth therein, the
non-breaching Party may terminate this Agreement without further notice. The
non-breaching Party shall have the right to recover all damages and losses
arising as a result of any such material breach, provided that any such recovery
shall be reduced by the amount that such non-breaching Party actually recovers
under any insurance it maintains.

10.2 Termination for Talecris' Force Majeure. Customer may terminate this
Agreement in its sole discretion upon written notice in the event of any failure
or inability of Talecris extending beyond sixty (60) days to provide Cryo
hereunder due to Force Majeure. In the event of termination under this Section
10.2, Talecris shall have no liability for damages arising solely from such
termination or otherwise excused by a Force Majeure.

                                  Page 14 of 30

<PAGE>

10.3 Other Termination Provisions, By Customer if Talecris or by Talecris if
Customer:

     (i)  admits in writing that it is unable to pay its debts as they become
          due;

     (ii) starts a proceeding, or indicates its acquiescence to a proceeding
          started by another, relating to it under any bankruptcy,
          reorganization, rearrangement, insolvency, readjustment or debt,
          dissolution, liquidation or similar law;

     (iii) makes an assignment for the benefit of creditors;

     (iv) consents to the appointment of a receiver, trustee or liquidator for a
          substantial part of its property;

     (v)  files, or has filed against it, a petition in bankruptcy,
          reorganization, rearrangement or insolvency which, if filed against
          it, is not dissolved or dismissed within ninety (90) days after
          filing; or

     (vi) had entered against it an order by a court of competent jurisdiction
          appointing a receiver, trustee or liquidator for it or a substantial
          part of its property, or approving its dissolution or termination, and
          if not consented to or acquiesced in by such Party, such order in not
          vacated or set aside or stayed within ninety (90) days.

Notwithstanding anything to the contrary herein, no Party shall take or cause to
be taken any action relating to the voluntary liquidation or dissolution of such
Party.

10.4 Effect of Termination. Upon termination of this Agreement, Talecris shall
immediately cease delivery of all Cryo under this Agreement, and Talecris shall
prepare and submit to Customer an invoice for all Cryo shipped by Talecris and
not paid for by Customer. Customer shall within thirty (30) days of receipt
thereof pay the full amount of such invoice and all other sums owed to Talecris;
provided, however, that if the aggregate total of the Purchase Orders placed by
Customer prior to the effective date of such termination does not meet the
Binding Forecast for the then current calendar year in the event that this
Agreement is terminated by Talecris pursuant to Section 10.1, Customer shall be
obligated to pay amounts associated with Cryo to be delivered under the then
current Binding Forecast and, at Customer's sole discretion, Talecris shall be
obligated to deliver the same.

10.5 Remedies. The rights of a Party to this Agreement to recover monetary
damages from the other Party to this Agreement with respect to termination of
this Agreement are exclusively set forth in this Section 10.

10.6 Survival. Provisions of this Agreement, which by their nature would
continue beyond the termination, expiration or ending in any other way of this
Agreement shall survive the termination, expiration or ending in any other way
of this Agreement.

                                  Page 15 of 30
<PAGE>

                           SECTION 11: INDEMNIFICATION

11.1 Indemnification: Talecris, Talecris hereby agrees to save, defend and hold
Customer and its affiliates and its or their directors, officers, managers,
employees, representatives, consultants, stockholders, controlling persons and
agents and each of the heirs, executors, successors and assigns of any of the
foregoing (together, the "CUSTOMER GROUP") harmless from and against any and all
claims, suits, actions, liabilities, expenses and/or losses, including punitive
or exemplary damages and reasonable attorneys' fees and expenses ("CLAIMS")
asserted by a person or entity other than a member of the Customer Group arising
from any material breach of obligations under this Agreement by Talecris Group
(as defined below).

11.2 Indemnification: Customer. Customer hereby agrees to save, defend and hold
Talecris and its affiliates and its or their directors, officers, managers,
employees, representatives, consultants, stockholders, controlling persons and
agents and each of the heirs, executors, successors and assigns of any of the
foregoing (together, the "TALECRIS GROUP") harmless from and against any and all
Claims asserted by a person or entity other than a member of the Talecris Group
arising from any material breach of obligations under this Agreement by the
Customer Group.

11.3 Joint Responsibility. Where a Claim arises directly or indirectly from acts
or omissions of both (i) the Talecris Group and (ii) the Customer Group, the
obligation of the Talecris or Customer to indemnify the other shall not exceed
the extent of the indemnifying party's contribution to the harm giving rise to
the Claim.

                           SECTION 12: CONFIDENTIALITY

12.1 Confidentiality Obligations. All information provided by one Party to the
other Party in connection with this Agreement (including without limitations,
the Specifications and forecasts provided by Customer) shall be maintained in
strict confidence by the receiving Party. Such information shall remain the
property of the providing Party, and the receiving Party shall not make use of
any such information except for the purposes for which it was provided. At the
termination of this Agreement, the receiving Party shall promptly return to the
providing Party any physical embodiments (including copies) of any such
information. Each Party agrees to keep confidential the existence of this
Agreement, as well as all of its terms and conditions; provided that if a public
announcement-or disclosure is required by law, rule, regulation, court order,
subpoena, interrogatory or other discovery request (including without limitation
applicable securities laws or stock exchange regulations), and subject to
Section 12.2(vi), the Party required to make the public announcement or
disclosure shall be permitted to make such disclosure and shall provide prompt
prior written notice of such requirement to the other Party, and the Parties
shall thereafter negotiate in good faith, to the extent appropriate and
feasible, the contents of the public announcement or disclosure.

12.2 Exceptions. The covenants of the receiving Party contained in Section 12.1
shall not apply to information which: (i) is already in the public domain at the
time of disclosure; (ii) becomes part of the public domain through no action or
omission of the receiving Party after disclosure to the receiving Party; (iii)
is already known to the receiving Party at the time of disclosure, as evidenced
by the receiving Party's written records; (iv) has been or is disclosed to the
receiving Party in good faith by a third party who was or is not, at the time of
disclosure, under any obligation of confidence to the other Party hereto at the
time the third party disclosed such information; (v) is independently developed
by the receiving Party, without reliance on information provided by the
disclosing party, as evidenced by the receiving Party's written records, or (vi)
is required to be disclosed by law, provided that the receiving Party shall
cooperate with the disclosing Party (at the disclosing Party's expense) in
obtaining any available protection for such information to be disclosed.
Talecris acknowledges that Customer currently manufactures its own Cyo and uses
know how developed by Customer or received from third parties for such
purchases.

                                  Page 16 of 30

<PAGE>

12.3 Other Confidentiality Agreements. In the event that the Parties are bound
by more than one confidentiality agreement, then the obligations contained
therein shall be deemed cumulative.

                              SECTION 13 INSURANCE

Each Party shall procure and maintain, at its own expense, in full force and
effect at all times during the term, product liability insurance written by a
responsible insurance carrier, Best Rated A, with a combined single limit of not
less than five million U.S. dollars (U.S. $5,000,000). Such insurance policy
shall name both Parties hereto as additional insureds and will provide for at
least thirty (30) days prior written notice to the other Party of the
cancellation or substantial adverse modification thereof. Each Party hereto
shall deliver a certificate of such insurance to the other Party promptly upon
issuance of the policy and shall, from time to time as reasonably requested by
such other Party, furnish such other Party with evidence of the maintenance
thereof. If any of the insurance policies described herein are written on a
claims made basis, the applicable Party maintaining such insurance agrees either
to (a) continue to purchase such coverage or (b) purchase an extended reporting
period endorsement ("tail" insurance), in either instance for the entire Term,
and for a period of five (5) years after the end of such Term.

                            SECTION 14 MISCELLANEOUS

14.1. Consent to Assignment. This Agreement and all of the provisions hereof
shall be binding upon and inure to the benefit of the parties hereto and their
respective successors and assigns, and are not intended to confer upon any other
person any rights or remedies hereunder. Neither this Agreement nor any of the
rights, interests or obligations hereunder may be assigned by any of the parties
without the prior written consent of the other party hereto, except that each
party may at any time assign any or all of its rights or obligations hereunder
to one of its wholly owned subsidiaries (but no such assignment shall relieve
such party of any obligations under this Agreement). Notwithstanding the
foregoing, Talecris may assign this Agreement and any or all rights or
obligations hereunder to (i) any affiliate of Talecris, provided that any such
affiliate becomes a party to this Agreement prior to such assignment or (ii) any
successor in interest to Talecris, it being understood that any such successor
shall commit to Customer to continue to supply Cryo under this Agreement from
the Precision Pharma Services Facility; and provided that any such successor
becomes a party to this Agreement. No assignment under (i) or (ii) above shall
relieve Talecris from any obligation hereunder. Customer may assign this
Agreement and any or all rights or obligations hereunder to (i) any affiliate of
Customer provided that any such affiliate becomes a party to this Agreement or
(ii) any successor in interest to Customer of its fibrin sealant business,
provided that any such successor becomes a party to this Agreement. No
assignment under (i) or (ii) above shall relieve Customer nom any obligation
hereunder. Any purported assignment in contravention of this Section 14.1 shall
be void.

14.2 Entire Agreement and Amendments. Except with regards to additional
confidentiality agreements, this Agreement, together with the Exhibits,
constitutes the entire agreement between the Parties regarding the supply of
Cryo, whether oral or written, relating to the subject matter hereof. In the
event that this Agreement conflicts with any Purchase Order, invoice or other
written document, the terms and conditions of this Agreement shall apply. No
amendment, modification or interpretation of this Agreement will have any effect
unless it is reduced to writing, makes specific reference to this Agreement and
is signed by all of the Parties.

14.3 Notices. All notices, requests, demands and other communications required
or permitted hereunder shall be in writing and if mailed by prepaid first class
mail or certified mail, return receipt requested, at any time other than during
a general discontinuance of postal service due to strike, lockout or otherwise,
shall be deemed to have been received on the earlier of the date shown on the
receipt or three (3) business days after the postmarked date thereof and, if
telexed or faxed, the original notice shall be mailed

                                  Page 17 of 30

<PAGE>

by prepaid first class mail within twenty-four (24) hours after sending such
notice by telex or fax, and shall be deemed to have been received on the
business day following dispatch and acknowledgment of receipt the recipient's
telex or telecopy machine. In addition, notices hereunder may be delivered by
hand, in which event the notice shall be deemed effective when delivered, or by
overnight courier, in which event the notice shall be deemed to have been
received on the next business day following delivery to such courier. All
notices and other communications under this Agreement shall be given to the
parties hereto at the following addresses:

     (a)  If to Customer:

          Omrix Biopharmaceuticals, Ltd
          MDA Blood Center, Tel Hashomer
          Hospital, Tel Aviv 52621 Israel
          Attn: Robert Taub
          President and CEO

     (b)  If to Talecris:

          Talecris Biotherapeutics, Inc.
          79 TW Alexander Drive
          4101 Research Commons
          Research Triangle Park
          Raleigh, NC 27709 USA
          Fax: (919)316-6677
          Attention: Law and Public Affairs Department

          And to:

          Talecris Biotherapeutics, Inc.
          8368 U.S. 70 West
          Clayton, NC 27520 USA
          Attn.: Anne Davis

     Any Party hereto may change its address specified for notices herein by
     designating a new address by notice in accordance with this Section 14.3.

14.4 Independent Contractor. This Agreement does not create an employer-employee
relationship between the Parties, and is not an agency, joint venture or
partnership. Neither Party shall have the authority to act for the other or to
bind the other in any way, nor to sign the name or to represent that the other
is in any way responsible for the acts or omissions of the other. Talecris shall
maintain its status as an independent contractor engaged in the selling of Cryo
to Customer.

14.5 Non-Waiver. The waiver by either party of any breach of any term, covenant,
condition or agreement contained herein or any default in the performance of any
obligations hereunder shall not be deemed to be a waiver of any other breach or
default of the same or of any other term, covenant, condition, agreement or
obligation.

14.6 Choice of Law. The rights and obligations of the Parties arising out of the
Agreement shall be governed in all respects by the laws of the State of New
York, without giving effect to its conflict of laws provisions.

                                  Page 18 of 30
<PAGE>

14.7 Captions. All captions are inserted for convenience only, and will not
affect any construction or interpretation of this Agreement.

14.8 Severability. Any provision of this Agreement which is or may become
prohibited or unenforceable, as a matter of law or regulation, will be
ineffective only to the extent of such prohibition or unenforceability and shall
not invalidate the remaining provisions hereof if the essential purposes of this
Agreement may be given effect despite the prohibition or unenforceability of the
affected provision.

14.9 Dispute Resolution.

     (a) Resolution by the Parties. The Parties shall attempt to resolve any
     dispute, controversy, claim or difference arising out of, or in connection
     with, this Agreement amicably and promptly by negotiations between
     executives who have authority to settle the controversy. Either Party may
     give written notice of any dispute not resolved in the normal course of
     business ("NOTICE OF DISPUTE"). Within seven (7) days after delivery of
     such Notice of Dispute, executives of the Party shall agree to meet at a
     mutually acceptable time and place, and thereafter as often as they
     reasonably deem necessary, to attempt to resolve the dispute. If the matter
     has not been resolved within ten (10) days of the first meeting of such
     executives (or, if the Parties are unable to mutually agree upon an
     acceptable time and place to meet, within ten (10) days of the disputing
     Party's Notice of Dispute) either Party may, by notice to the other Party
     ("DISPUTE ESCALATION NOTICE"), refer the matter to the respective officers
     of the Parties designated below.

          For Customer:
                        Omrix Biopharmaceuticals, Ltd
                        MDA Blood Center,
                        Tel Hashomer Hospital, Tel Aviv 52621 Israel
                        Attn: Robert Taub
                        President and CEO

          For Talecris:
                        Talecris Biotherapeutics, Inc.
                        79 TW Alexander Drive
                        4101 Research Commons
                        Research Triangle Park
                        Raleigh, NC 27709
                        Fax: (919)316-6677
                        Attn: Chief Executive Officer of Talecris
                              Biotherapeutics, Inc.
                        With a copy to: VP, General Counsel

          And to:
                        Talecris Biotherapeutics, Inc.
                        8368 U.S. 70 West
                        Clayton, NC 27520 USA
                        Attn.: Anne Davis

     Such officers shall negotiate in good faith to resolve the matter in an
     amicable manner within ten (10) days of the Dispute Escalation Notice. In
     the event the matter is not resolved within such ten (10) days, either
     Party may initiate arbitration of the dispute as provided for in this
     Section 14.9.

     (b) Binding Arbitration. In any event, if any dispute is not resolved in
     accordance with Section 14.9(a) within thirty (30) days of the date in
     which such dispute arose, either Party may

                                  Page 19 of 30

<PAGE>

     Association (the "RULES"). If the arbitrator is not agreed by the Parties
     within a thirty (30) day period, then the arbitrator will be selected by
     the American Arbitration Association. The arbitration shall be held in the
     English language in New York, New York (U.S.) in accordance with the
     substantive law of the State of New York, without giving effect to its
     conflict of laws provisions. Notwithstanding the provisions of this Section
     14.9, Party shall be entitled to seek injunctive relief or specific
     performance in a court of competent jurisdiction in cases where a breach of
     this Agreement may cause the other Party extensive and irreparable harm and
     damage.

14.10 Set-Off. No Party to this Agreement shall have any right of set off with
respect to amounts it has an obligation to pay hereunder.

14.11 Conflicting Terms. In the event any terms of the exhibits conflict with
this Agreement, the terms of this Agreement shall control.

IN WITNESS WHEREOF, the Parties have caused their duly authorized
representatives to execute this Agreement as of the Effective Date.

                                        OMRIX

                                        By: /s/ Robert Taub
                                            ------------------------------------
                                        Name: Robert Taub
                                        Title: President and CEO

                                        TALECRIS BIOTHERAPEUTICS, INC.

                                        By: /s/ Mary J Kuhn
                                            ------------------------------------
                                        Name: Mary J Kuhn
                                        Title: SVP Operations

                                                                         (STAMP)

                                  Page 20 of 30

<PAGE>

                                    EXHIBIT A

                               Required Quantity*

<TABLE>
<CAPTION>
Anniversary Year after Commencement Date   Kgs of Cryo
----------------------------------------   -----------
<S>                                        <C>
                    1                           ***
                    2                           ***
                    3                           ***
                    4                           ***
                    5                           ***
                    6                           ***
                    7                           ***
</TABLE>

*    Such quantities may be adjusted in accordance with Section 2.

                                 Page 21 of 30
<PAGE>

                                    EXHIBIT B

     FIRST ANNIVERSARY YEAR CRYO FORECAST

<TABLE>
<CAPTION>
            Cryo
  Month    (kgs)
  -----    -----
<S>        <C>
     XX
    XX+1
    XX+2
    XX+3
    XX+4
    XX+5
    XX+6
    XX+7
    XX+8
    XX+9
   XX+10
   XX+11
Total
</TABLE>

Approved by
            -----------------------------
            Talecris

Approved by
            -----------------------------
            Customer

                                  Page 22 of 30

<PAGE>

                               EXHIBIT B (CONT'D.)

     SECOND ANNIVERSARY YEAR CRYO FORECAST

<TABLE>
<CAPTION>
            Cryo
  Month    (kgs)
  -----    -----
<S>        <C>
     XX
    XX+1
    XX+2
    XX+3
    XX+4
    XX+5
    XX+6
    XX+7
    XX+8
    XX+9
   XX+10
   XX+11
Total
</TABLE>

Approved by
            -----------------------------
            Talecris

Approved by
            -----------------------------
            Customer

                                  Page 23 of 30

<PAGE>

                               EXHIBIT B (CONT'D.)

     THIRD ANNIVERSARY YEAR CRYO FORECAST

<TABLE>
<CAPTION>
            Cryo
  Month    (kgs)
  -----    -----
<S>        <C>
     XX
    XX+1
    XX+2
    XX+3
    XX+4
    XX+5
    XX+6
    XX+7
    XX+8
    XX+9
   XX+10
   XX+11
Total
</TABLE>

Approved by
            -----------------------------
            Talecris

Approved by
            -----------------------------
            Customer

                                  Page 24 of 30

<PAGE>

                               EXHIBIT B CONTINUED

     FOURTH ANNIVERSARY YEAR CRYO FORECAST

<TABLE>
<CAPTION>
            Cryo
  Month    (kgs)
  -----    -----
<S>        <C>
     XX
    XX+1
    XX+2
    XX+3
    XX+4
    XX+5
    XX+6
    XX+7
    XX+8
    XX+9
   XX+10
   XX+11
Total
</TABLE>

Approved by
            -----------------------------
            Talecris

Approved by
            -----------------------------
            Customer

                                  Page 25 of 30

<PAGE>

                               EXHIBIT B (CONT'D.)

     FIFTH ANNIVERSARY YEAR CRYO FORECAST

<TABLE>
<CAPTION>
            Cryo
  Month    (kgs)
  -----    -----
<S>        <C>
     XX
    XX+1
    XX+2
    XX+3
    XX+4
    XX+5
    XX+6
    XX+7
    XX+8
    XX+9
   XX+10
   XX+11
Total
</TABLE>

Approved by
            -----------------------------
            Talecris

Approved by
            -----------------------------
            Customer

                                  Page 26 of 30

<PAGE>

                               EXHIBIT B (CONT'D.)

     SIXTH ANNIVERSARY YEAR CRYO FORECAST

<TABLE>
<CAPTION>
            Cryo
  Month    (kgs)
  -----    -----
<S>        <C>
     XX
    XX+1
    XX+2
    XX+3
    XX+4
    XX+5
    XX+6
    XX+7
    XX+8
    XX+9
   XX+10
   XX+11
Total
</TABLE>

Approved by
            -----------------------------
            Talecris

Approved by
            -----------------------------
            Customer

                                  Page 27 of 30

<PAGE>

                                    EXHIBIT C
                            CRYOPRECIPITATE ("CRYO")
                         SPECIFICATIONS AND REQUIREMENTS

                                  Page 28 of 30
<PAGE>

<TABLE>
<S>                              <C>                            <C>
(TALECRIS BIOTHERAPEUTICS LOGO)  STANDARD OPERATING PROCEDURES  SOP#: CS-000-AD-218
                                                                REVISION: 04
                                 TITLE: Preparation Of          PAGE 1 of 1
                                      Manufacturing Agreements  ATTACHMENT 2
                                      For The Purchase And
                                      Sale Of Plasma
                                      Intermediates
</TABLE>

                   INTERMEDIATE PRODUCT SPECIFICATION APPROVAL

Supercedes: N/A

The attached specifications for Cryoprecipitate that is purchased from Talecris
                                ---------------                        --------
                                 Intermediate                           Seller
by Omrix have been found acceptable.
   -----
   Buyer

These specifications will be effective:                   11 Sept. 2006.
                                                       ---------------------
                                                               Date

The revision number of these specifications will be:           NEW.
                                                       ---------------------

Associated Change Control Number:                               1.
                                                       ---------------------
                                                       N/A if not applicable

Talecris SAP Number: 1

Talecris Biotherapeutics, Inc.          Omrix approval:
approval:

/s/ Anne Davis
-------------------------------------   Refer to attached EAD 9-5-06
Date: 8-21-06                           Date:
Sr. Contract Manager                          ----------------------------------
                                        Title:
                                               ---------------------------------

/s/ Amy W. Durham
-------------------------------------   N/A EAD 9-11-06
Date: 8-30-06                           Date:
QO Manager                                    ----------------------------------
                                        Title:
                                               ---------------------------------

Comments: (1) A change control will be initiated at Talecris to create a SAP
number for traceability of material sold to Omrix. This CCR must be closed prior
to first shipment. EAD 8-21-06.

<PAGE>

<TABLE>
<S>                              <C>                            <C>
(TALECRIS BIOTHERAPEUTICS LOGO)  STANDARD OPERATING PROCEDURES  SOP#: CS-000-AD-218
                                                                REVISION: 04
                                 TITLE: Preparation Of          PAGE 1 of 1
                                      Manufacturing Agreements  ATTACHMENT 2
                                      For The Purchase And
                                      Sale Of Plasma
                                      Intermediates
</TABLE>

                   INTERMEDIATE PRODUCT SPECIFICATION APPROVAL

Supercedes: N/A

The attached specifications for Cryoprecipitate that is purchased from Talecris
                                ---------------                        --------
                                  Intermediate                          Seller
by Omrix have been found acceptable.
   -----
   Buyer

These specifications will be effective:                                     .
                                                       ---------------------
                                                               Date

The revision number of these specifications will be:            NEW.
                                                       ---------------------

Associated Change Control Number:                               1.
                                                       ---------------------
                                                       N/A if not applicable

Talecris SAP Number: 1

Talecris Biotherapeutics, Inc.          Omrix approval:
approval:

/s/ Anne Davis                          /s/ Karin Baer
-------------------------------------   ----------------------------------------
Date: 8-21-06                           Date: Sept 3, 2006
Sr. Contract Manager                    Title: Director QA

/s/ Amy W. Durham
-------------------------------------   ----------------------------------------
Date: 8-30-06                           Date:
QO Manager                                    ----------------------------------
                                        Title:
                                               ---------------------------------

Comments: (1) A change control will be initiated at Talecris to create a SAP
number for traceability of material sold to Omrix. This CCR must be closed prior
to first shipment. EAD 8-21-06

<PAGE>

                            CRYOPRECIPITATE ("CRYO")
                         SPECIFICATIONS AND REQUIREMENTS

<TABLE>
<S>                        <C>             <C>                      <C>

/s/ Amy W. Durham          Aug. 30, 2006   Refer to attached.       EAD 9-5-06
------------------------   -------------   ----------------------   ----------
Talecris Quality Manager   Date            Omrix Quality Director   Date

/s/ Allen D. William       09/08/2006
------------------------   ----------
Precision Pharma           Date
Services, Director,
Regulatory Affairs and
Quality Assurance
</TABLE>

Revision: NEW                                       Date Effective: 11 Sept 2006

     1.   PURPOSE

          To provide specifications for Cryo manufactured by the Precision
          Pharma Services Inc USA on behalf of and from plasma provided by
          Talecris Biotherapeutics, Inc USA, to assure that the starting raw
          material (Human Normal Source Plasma) and the manufactured material
          (Cryo) meets specifications and established guidelines and standards.

     2.   REFERENCES

          U.S. Code of Federal Regulations 21 CFR part 640 (appropriate
          sections).

     3.   PLASMA REQUIREMENTS

          The Cryo must be manufactured from Human Normal Source Plasma meeting
          all current FDA requirements, including testing and screening
          requirements. Source Plasma donations can only be accepted from
          regular, repeat (Qualified) donors. Anti D reclassified Plasma is not
          acceptable.

          3.1  Human Normal Source Plasma for the manufacturing of Cryo must be
               harvested from FDA licensed and approved collection centers,
               currently certified under the Plasma Protein Therapeutics
               Association's (PPTA)

               The Centers and all associated testing laboratories (including
               Talecris' NAT test lab) have received the Clinical Laboratory
               Inspection Act (CLIA) licensure and approval.

          3.2  Donor selection as well as collection, production, quality
               control and storage of plasma are in compliance with the current
               WHO and FDA regulations and standards. No plasma is collected
               from high risks populations; epidemiological data is available
               for each collection center. The information will be provided on
               an annual basis as part of the plasma master file.

          3.3  The anticoagulant and container quality is in compliance with the
               FDA requirements.

          3.4  The Plasma used for the Cryo production must be less than three
               (3) years from date of donation.

          3.5  The plasma once collected must be frozen rapidly at not warmer
               than -20 degrees C, within one (1) hour and maintained at or
               below minus

                                   Page 1 of 7

<PAGE>

                            CRYOPRECIPITATE ("CRYO")
                         SPECIFICATIONS AND REQUIREMENTS

<TABLE>
<S>                            <C>             <C>                      <C>

/s/ Amy W. Durham              Aug. 30, 2006   /s/ Karin Baer           Sept. 3, 2006
----------------------------   -------------   ----------------------   -------------
Talecris Quality Manager       Date            Omrix Quality Director   Date

----------------------------   -------------
Precision Pharma Services,     Date
Director, Regulatory Affairs
and Quality Assurance
</TABLE>

Revision: NEW                                  Date Effective:
                                                               -----------------

1.   PURPOSE

     To provide specifications for Cryo manufactured by the Precision Pharma
     Services Inc USA on behalf of and from plasma provided by Talecris
     Biotherapeutics, Inc USA, to assure that the starting raw material (Human
     Normal Source Plasma) and the manufactured material (Cryo) meets
     specifications and established guidelines and standards.

2.   REFERENCES

     U.S. Code of Federal Regulations 21 CFR part 640 (appropriate sections).

3.   PLASMA REQUIREMENTS

     The Cryo must be manufactured from Human Normal Source Plasma meeting all
     current FDA requirements, including testing and screening requirements.
     Source Plasma donations can only be accepted from regular, repeat
     (Qualified) donors. Anti D reclassified Plasma is not acceptable.

     3.1  Human Normal Source Plasma for the manufacturing of Cryo must be
          harvested from FDA licensed and approved collection centers, currently
          certified under the Plasma Protein Therapeutics Association's (PPTA)

          The Centers and all associated testing laboratories (including
          Talecris' NAT test lab) have received the Clinical Laboratory
          Inspection Act (CLIA) licensure and approval.

     3.2  Donor selection as well as collection, production, quality control and
          storage of plasma are in compliance with the current WHO and FDA
          regulations and standards. No plasma is collected from high risks
          populations; epidemiological data is available for each collection
          center. The information will be provided on an annual basis as part of
          the plasma master file.

     3.3  The anticoagulant and container quality is in compliance with the FDA
          requirements.

     3.4  The Plasma used for the Cryo production must be less than three (3)
          years from date of donation.

     3.5  The plasma once collected must be frozen rapidly at not warmer than
          -20 degrees C, within one (1) hour and maintained at or below minus

                                   Page 1 of 7

<PAGE>

          20 degrees C (-20 degrees C) during storage and transportation
          according to current CFR regulations.

     3.6  A certification for each Cryo shipment will be provided, indicating
          that the plasma was stored and shipped at a temperature at or below
          minus 20 degrees C. (-20 degrees C).

     3.7  Testing Required for each Unit of Plasma

          3.7.1 Each unit of plasma used for manufacture of the Cryo must be
               tested and found non-reactive for: hepatitis B surface antigen
               (HBsAg), antibodies to human immunodeficiency virus types 1 and 2
               (anti-HIV I/II), antibody to hepatitis C virus (anti-HCV) by
               current generation FDA-approved test methods. Additionally, once
               every four months the plasma donors are tested for Syphilis and
               found to be negative.

          3.7.2 Each plasma unit must be NAT/PCR tested and found negative for
               HAV, HBV, HIV-1, HCV and non-elevated for Parvo B19.

          Test Requirements for each unit:

<TABLE>
<CAPTION>
      TEST TYPE                            Test Requirements
      ---------        -----------------------------------------------------
<S>                    <C>
HBsAg(1)               Non-Reactive(2)
Anti-HIV 1/2(1)        Non-Reactive(2)
Anti-HCV(1)            Non-Reactive(2)
Syphilis(3)            Negative or Non-reactive for donor (test performed on
                       donor initially and every four (4) months)
Atypical Antibody(6)   Negative for donor (initial donation)
HIV-1 NAT(1)           Not Implicated(4)
HAV NAT(5)             Not Implicated(4)
HBV NAT(1)             Not Implicated(4)
HCV NAT(1)             Not Implicated(4)
Parvo B19 NAT(5)       Non-Elevated
</TABLE>

Notes:

(1.) Current generation, FDA approved test method must be used.

(2.) Some manufacturer's package inserts use the term "negative" and
     "non-reactive" interchangeably.

(3.) FDA approved syphilis test.

(4.) Some manufacturer's package inserts use the term "negative" and
     "not-implicated" interchangeably.

(5.) Currently not FDA approved test method. Upon approval, FDA approved methods
     must be used.

(6.) Test reagents for atypical antibody screening tests must minimally include
     specific anti-D antibody.

     3.8  Testing required for Plasma Pool

          3.8.1 The plasma pool used for manufacture of the cryoprecipitate must
               be tested and found non-reactive for HBsAg, anti-HIV I/II and
               HIV-1,

                                   Page 2 of 7

<PAGE>

               HBV, HAV and HCV-RNA by PCR/NAT. The plasma pool must be tested
               and found non-elevated for Parvo B19.

          3.8.2 Talecris will test each Plasma Pool to ensure the following
               quality limits (Omrix limits) are met:

          PLASMA POOL QUALITY LIMITS:

<TABLE>
<CAPTION>
  TEST TYPE            Test Requirements
  ---------     -------------------------------------
<S>             <C>
HBsAg           Non-reactive
Anti HIV-1/2    Negative
Anti-D          Non-Detectable (<1:1)
HIV-1 NAT       Negative
HAV NAT         Negative
HBV NAT         Negative
HCV NAT         Negative
Parvo B19 NAT   Non-Elevated (< or = 1 x 10(5) IU/mL)
</TABLE>

          3.8.3 Omrix will test each Plasma Pool to ensure Omrix internal
               specifications are met prior to authorizing shipment of specific
               batches. Omrix will perform the following tests.

          PLASMA POOL:

                                    TEST TYPE
                       Protein (Biuret)
                       TVC

     3.9  Representative pre-delivery samples (3 x 10 mL) of the Manufacturing
          Pool associated with each batch of Cryoprecipitate offered for sale to
          Omrix will be supplied to Omrix for evaluation.

          Based on the plasma pool certification and results of testing by
          Talecris/Precision and Omrix, Omrix will approve the shipment no later
          than 30 days after receipt of samples.

     3.10 The actual number of donors represented in the plasma pool from which
          an amount of approximately 20 kg of Cryo is derived does not exceed
          5700 donors.

4.   CRYO REQUIREMENTS

     4.1  The Cryo must be manufactured by Precision Pharma Services Inc USA
          under the responsibility of Talecris Biotherapeutics, Inc. USA. The
          manufacturing process must be approved and licensed by the FDA.

     4.2  The Cryo batch size (derived from one plasma pool only) should be as
          big as possible, but not less than 10kg.

     4.3  The Cryo to be sent to Omrix must be less than 6 months old from
          production date.

                                   Page 3 of 7
<PAGE>

     4.4  The storage and shipping temperature of Cryo must be minus 20 degrees
          C (-20 degrees C) or colder.

     4.5  Cryo must meet the Material specifications as detailed by Precision
          Pharma Services Inc USA under the responsibility of Talecris
          Biotherapeutics, Inc. USA and which are to be provided to Omrix.

     4.6  Representative pre-delivery samples (5 x l0gr) of each batch of Cryo
          (prior to freezing) will be supplied to Omrix to be tested by Omrix
          prior to purchasing Cryo for further manufacturing in a Fibrin Sealant
          product. Precision Pharma Services will release individual batches of
          Cryo based on their FDA BLA requirements. Omrix will authorize
          shipment of individual batches of Cryo based on the batch meeting the
          following quality limits (Omrix limits) after re-suspension and
          testing of the pre-delivery samples is performed at Omrix:

<TABLE>
<CAPTION>
PARAMETERS                LIMITS
----------            --------------
<S>                   <C>
Total protein         30-60mg/ml
% Clottable Protein   > or = 60%
Fibrinogen            20-40mg/ml
Factor XIII           2-9IU/ml
Factor VIII           5-20IU/ml
Fibronectin           0.5-6.0
VWFAg                 15-40IU/ml
TWC                   <3000 CFU/mL
</TABLE>

          Based on Cryo sample results tested by Omrix, and Plasma Pool results
          (tested by Talecris/Omrix), Omrix will approve the shipment of the
          Cryo batch no later than 30 days after receipt of samples.

5.   GENERAL REQUIREMENTS:

     5.1  The following Plasma supplier information must be maintained for each
          center currently supplying plasma to Talecris by the Quality
          Organization at Talecris.

               1.   FDA approved ELA, PLA or BLA

               2.   CLIA registration certificate for the facility

               3.   Individual state licenses, as required

               4.   iQPP certification for the collection facility

               5.   FDA approved SOP manual

               6.   Viral Marker Rates - provided no less than quarterly

               7.   US FDA Form 483, inspection observations and
                    follow-up/corrective actions

               8.   Talecris Quality Compliance Audits - conducted on a periodic
                    basis, not less than once every 24 months.

     5.2  U.S. Plasma Master File should be submitted once to Omrix and then
          when versions are updated or new versions are issued.

                                  Page 4 of 7

<PAGE>

          The Plasma Master File should include the following information:

          1.   A list of names and addresses of blood/plasma collection
               establishments including any subcontractors and any separate
               sites for testing of individual donations.

               NOTE: The Plasma Master File is updated on an annual basis. The
                    list of centers currently supplying plasma to Talecris is
                    maintained by Talecris' Quality Organization.

          2.   Conditions of storage and transportation of the plasma

          3.   Epidemiological data on blood transmissible infections.

          4.   Selection/Exclusion Criteria

          5.   Donation traceability

          6.   Suitability of donors

          7.   Donor record system

          8.   Test result Management for laboratory results

          9.   Donor frequency and volume.

          10.  Screening of donations

               List of all tests performed (including NAT testing) on individual
               donations, minipools and plasma pools (if relevant), the test
               method, brand name of test kit, manufacturer, generation of test,
               license number and countries where licensed, plus validation of
               screening test methods.

          11.  Donor registration and applicant donor system

          12.  Donor deferral system

          13.  Look back procedures.

          14.  Post collection information system.

          15.  Batch numbering system

          16.  Information on the containers used for collection and of the
               anticoagulant solution.

          17.  Confirmation that all preventive measures are taken to reduce the
               possible risk of transmission of Creutzfeldt -Jacob disease (CJD)
               and variant Creutzfeldt -Jacob disease (vCJD) in blood and blood
               products.

     5.3  Any changes to the test kits used for the plasma testing must be
          notified in writing to Omrix at least 60 days prior to the shipment of
          any plasma using such changed test kits. Documentation on the test
          kits validation must be provided.

     5.4  A full description of the process for Cryo production must be provided
          to Omrix.

     5.5  Precision Pharma must receive written approval prior to shipment of a
          Cryo batch to Omrix.

     5.6  Manufacturing records for the production of Cryo including
          traceability to the individual plasma units will be kept on file per
          all FDA regulations.

          Manufacturing records and Bleeding lists (electronic data/hard copy)
          for each plasma pool are available for inspection by Omrix upon
          request.

     5.7  Consistent with Section 6.2 of the Supply Agreement, Omrix has the
          right to inspect/audit relevant areas of the facilities and the
          relevant documentation associated with the supply of plasma and for
          the

                                   Page 5 of 7

<PAGE>

          manufacturing of Cryo typically once per year This rate may be
          adjusted whenever considered necessary. Omrix will notify Talecris and
          Precision Pharma three weeks prior to the proposed audit. Talecris
          will notify Omrix if the audit date is acceptable. If the audit date
          is not acceptable an alternate date will be provided.
          Talecris/Precision and Omrix will use commercially reasonable efforts
          to accommodate the audit date.

     5.8  Talecris Biotherapeutics Inc./Precision Pharma must inform Omrix about
          each change in the Manufacturing Process affecting any Key Process
          Parameters as defined in Exhibit D of the Supply Agreement that
          requires FDA prior approval. Notification must be made to Omrix at
          least six (6) months prior to implementation. This allows time for
          Omrix to evaluate the impact of the change to the product being
          processed by Omrix. Omrix may not accept batches of Cryo if they will
          not comply with the approved requirements and specifications.

6.   STORAGE AND SHIPPING REQUIREMENTS

     6.1  Packaging - The cryoprecipitate from a single batch must be frozen in
          separate entities weighing < or = 5 kg. These separate entities will
          be grouped into shipments of NMT 25 kg. Each shipment will be double
          bagged using two plastic liners. Cryoprecipitate will be shipped in
          plastic sealable containers. Each container is to be labeled inside
          and outside.

     6.2  Storage and Shipping - Cryoprecipitate must be stored at -20 degrees C
          or colder and shipped upon request to Omrix. Cryoprecipitate must be
          shipped at -20 degrees C or colder. The temperature of each shipment
          must be monitored by Omrix. If temperature monitoring devices are
          required, Omrix will provide the devices and instructions on
          activation. Shipments from Precision to Omrix will be made Ex Works.

7.0  CERTIFICATIONS

     7.1  For each batch of Cryo shipped to Omrix, Precision Pharma/Talecris
          must submit the following documentation:

          1.   Proforma-Invoice (to be sent prior to shipment).

          2.   Certificate of Quality which will include the following data (to
               be sent prior to shipment):

               -    Tests and results performed on each contributing plasma unit
                    and all plasma pools

               -    A statement certificating that the Cryo is of the same
                    quality as required for the marketing and human use of
                    plasma derivatives products in USA and certificating that
                    the Cryo was processed by Precision Pharma Services Inc USA
                    current U.S. licenses approved by United States Food and
                    Drug Administration (FDA) regulations, including that there
                    were no manufacturing deviations or discrepancies for this
                    batch that could adversely affect the safety, purity, or
                    potency of the Cryo and that the Cryo has not been reworked
                    or reprocessed. Complete data indicating the initial

                                   Page 6 of 7
<PAGE>

                    plasma volume, calculated numbers of donors in the pool,
                    date of plasma pooling, oldest and recent donation date,
                    Plasma pool batch number, total amount of Cryo produced,
                    date of Cryo manufacture.

8.0  ATTACHMENTS

     8.1  Example - Cryoprecipitate Certification of Analysis

                                   Page 7 of 7

<PAGE>

             Attachment 1 - Example Certificate of Cryoprecipitate
                         PRECISION PHARMA SERVICES. INC.
                                 155 Duryea Road
                            Melville, New York 11747
                               Phone: 631-752-7314
                                Fax: 631-752-7354

                         Certificate of Cryoprecipitate
                                    For Omrix

Paste Batch #: _____________            Date of Manufacture: _____________
Plasma Pool #: _____________            Plasma Volume: L
SAP#:          _____________            Number of Pooled Units: __________
Paste Weight:  kg __________

This paste was fractionated from Precision plasma pool # XXXXXXX. The paste
contained only the material from Talecris shipment pool # XXXXXXX. All plasma
units processed in this pool were 100% inspected. No additional units were added
to the pre-selected pool except as authorized in writing by Talecris (Copy
attached) and noted on the Plasma Packing List.

The plasma units used in the manufacture of this batch of Paste are collected in
the United States in facilities licensed by the U.S Food and Drug Administration
and inspected and approved by the FDA. These plasma units were collected from
healthy donors who met the criteria prescribed in 21 CFR, part 640.

All contributing plasma to this manufacturing pool has been tested and found
negative for HBsAg, anti-HIV-1/2, anti-HCV, HCV/HIV-1/HAV and HBV by NAT.
Donors, associated with these plasma units, were screened and found negative for
syphilis and undetectable for Anti-D, Additionally, the plasma units were
screened for parvovirus B19 by NAT and found non-elevated.

Oldest donation date: __________________
Most recent donation date: _____________

Manufacturing pool samples were tested by Talecris and found
negative/non-reactive for the following: HBsAg, Anti-D, HIV-1 & 2 Antibody, HCV/
HIV-1/HAV and HBV by NAT. Additionally, the manufacturing pool was tested for
parvovirus B19 by NAT and found non-elevated.

All lookback, positive, and other discrepant units were removed prior to
pooling.

This paste was processed in a manner minimizing microbial load and endotoxin
load.

The Cryoprecipitate batch has not been reworked for any reason.

The raw plasma was stored at -20 degrees C or less prior to Fractionation. The
intermediate stages were held at the required temperature ranges during the
process. Additionally, plasma was shipped from Talecris to Precision at
-20 degrees C or colder.

This paste was processed according to Precision procedures and BLA's and BLA
Amendments filed with and approved by CBER/FDA. The finished Cryoprecipitate was
held at -20 degrees C or colder prior to shipment.

Changes and/or variations in the process from those outlined on the production
records at Precision but with the constraints of the BLA and/or BLA Amendments
have been reviewed and approved by Precision and are appropriately documented in
the records. There were no significant deviations for this batch.

The Product Records for this batch are located at the Precision facility and are
available for further review by authorized personnel.

The plasma and the Paste are of the same quality as required for the marketing
and human use of plasma derivatives products in USA.

This batch was released by Precision Pharma Services, Inc.

I certify that the above information is correct.

-------------------------------------   ----------------------------------------
Quality Assurance                       Date

<PAGE>

                                   EXHIBIT D
   KEY PROCESS PARAMETERS - PRECISION PHARMA CRVOPRECIPITATE: FDA LICENSE 1633

The following steps are considered to be the critical steps:

     1.   Pre-thawing of plasma

          a.   Batch Size: Not defined in license

          b.   Temperature range: Plasma units are stored < or = -20 degrees C

          c.   Time: Not defined in license

     2.   Thawing

          a.   Temperature: Plasma is pooled and thawed at 0-4 degrees C

          b.   Agitation speed: Not defined in license

     3.   Centrifugation

          a.   Type of centrifuge/name: Westfalia BKA-28 or AS-26 Sharpies

          b.   Flow rate to centrifuge: Not defined in license

          c.   Centrifugation revolutions (rpm): Not defined in license

          d.   Plasma inlet temperature: Thawed plasma is 0 - 4 degrees C

          e.   Supernatant outlet temperature: Effluent temperature is 0 - 4
               degrees C

     4.   Cryo blast freezing

          a.   Freezer temperature: Not defined in license

          b.   Time limitation until freezing: Not defined in license

          c.   Minimal time for freezing: Not defined in license

          d.   Packaging material and cake height: Not defined in license

     5.   General:

          a.   Copy of Cleaning Procedures (including manual OP/SIP as
               applicable)

          b.   Thawing tank, centrifuge or freezer change

                                  Page 29 of 30

<PAGE>

                       EXHIBIT E--MANUFACTURING AGREEMENT

                                  Page 30 of 30
<PAGE>

Precision Pharma Services, Talecris Biotherapeutics, Inc.            Page 1 of 4
and Omrix Biopharmaceuticals Ltd.
Manufacturing Agreement (Cryoprecipitate)

                             MANUFACTURING AGREEMENT

This Manufacturing Agreement (Agreement) is between Omrix Biopharmaceuticals
Ltd. (Omrix) located at MDA Bloodbank, Sheba Hospital, Ramat Gan, POB 888,
Kiryat Ono 55000, Israel, Precision Pharma Services (Precision), located at 155
Duryea Road, Melville, New York 11747, and Talecris Biotherapeutics, Inc.
(Talecris), located at 79 T.W. Alexander Drive, 4101 Research Commons, Research
Triangle Park, North Carolina 27709. Precision manufactures Cryoprecipitate for
Talecris from US licensed Source Plasma (Human) supplied by Talecris to
Precision. The "Effective Date" is determined by the last date of the signature
of the authorized representatives of each party at the end of this Agreement.

Whereas the United States Food and Drug Administration (FDA) regulations allow
that a shipment or other delivery of a drug (biologic) which is, in accordance
with the practice of the trade, to be processed, labeled, or repacked in
substantial quantity at an establishment other than that where originally
processed or packed, shall be exempt, during the time of introduction and
movement in interstate commerce and the time of holding such establishment, from
compliance with the labeling and packaging requirements of Sections 501(b) and
502(b),(e),(f) and (g) of the Federal Food, Drug and Cosmetic Act [21 U.S.C.
351(b) and 352(b), (e), (f) and (g)], if the requirements of 21 CFR Section
201.150 are met and that a partially processed biological product may be
exported if requirements of Section 351(h) of the Public Health Service Act and
Section 801 (e)(1) of the Federal Food, Drug and Cosmetic Act are met.

NOW, THEREFORE, it is agreed as follows:

1.   INTENT OF PARTIES

          It is the express intent of the parties hereto to adhere to all of the
          requirements set forth at 21 CFR Section 201.150.

          It is the intent of Precision/Talecris to distribute Cryoprecipitate
          to Omrix solely for use in the manufacture of "Fibrin Sealant" under
          a shared manufacturing arrangement according to the CBER draft
          guideline "Cooperative Manufacturing Arrangements for Licensed
          Biologics". The cryoprecipitate may not be sold or used in the
          manufacture of any other product.

2.   MAINTENANCE OF PROPER RECORDS

          Each party agrees to maintain complete and adequate records, where
          applicable, pertaining to the methods used in and the facilities and
          controls used for the manufacture, processing, packing, labeling and
          holding of drugs and pertaining to the disposition of Plasma
          Cryoprecipitate (Cryoprecipitate), as may be required by applicable
          regulations.

<PAGE>

Precision Pharma Services, Talecris Biotherapeutics, Inc.            Page 2 of 4
and Omrix Biopharmaceuticals Ltd.
Manufacturing Agreement (Cryoprecipitate)

          It is further agreed that each party will maintain a copy of all
          records required pursuant to this Agreement until five (5) years after
          the final shipment or delivery of the Cryoprecipitate hereunder from
          the Precision manufacturing facility, and shall make copies available
          for inspection at any reasonable hour to any authorized representative
          of the Department of Health and Human Services.

3.   SPECIFICATIONS

          Cryoprecipitate will be manufactured under contract by Precision for
          Talecris from US licensed Source Plasma (Human) supplied by Talecris
          to Precision. Cryoprecipitate is a licensed intermediate for further
          manufacturing use manufactured by Precision.

          Precision will manufacture and ship bulk quantities of Cryoprecipitate
          to Omrix. Said material will be furnished in bulk containers, per
          Specifications, and will be labeled to indicate that further
          manufacturing, processing or repacking is intended. Cryoprecipitate
          will be fractionated by Precision from US Collected Source Plasma
          obtained in accordance with the provisions 21 CFR Section 640, Subpart
          G, and other applicable FDA guidelines and regulations including but
          not limited to 21 CFR Section 610.40, 610.41 and 610.46.
          Cryoprecipitate shall meet the current Specifications an example of
          which is attached hereto as Exhibit C (Specifications). If
          Specifications are revised during the term of this Agreement both
          parties will agree to all revisions prior to implementation.

          Each unit of plasma used in the manufacture of this material will be
          certified to have been tested and found nonreactive for Hepatitis B
          Surface Antigen (HBsAg), antibodies to Human Immunodeficiency Virus
          (HIV-1/HIV-2), antibodies to Hepatitis C virus (anti-HCV). Each unit
          of plasma used in the manufacture of Cryoprecipitate will also be
          certified by Talecris to have been NAT tested in mini-pools and found
          non-reactive for HAV, HIV-1, HBV, HCV. Furthermore, each plasma unit
          used in the manufacture of Cryoprecipitate will also be certified by
          Talecris to have been NAT tested in a mini-pools format for Parvovirus
          B19 and have shown no highly viraemic titers of Parvovirus B19,
          avoiding manufacturing pools exceeding 10(5) IU B19 DNA per mL, and
          will also meet any other applicable FDA testing and screening
          requirements.

          The plasma pool used in the manufacture of this material will be
          certified by Talecris to have been tested and found nonreactive for
          Hepatitis B Surface Antigen (HBsAg), antibodies to Human
          Immunodeficiency Virus (HIV-1/HIV-2), and HAV, HBV, HCV, and HIV-1 by
          NAT. The plasma pool will also be certified to have been tested by NAT
          for Parvovirus B19 and did not exceed 10(5) IU B19-DNA per mL.

<PAGE>

Precision Pharma Services, Talecris Biotherapeutics, Inc.            Page 3 of 4
and Omrix Biopharmaceuticals Ltd.
Manufacturing Agreement (Cryoprecipitate)

          The Cryoprecipitate will be stored and shipped at -20 degrees C or
          colder. Shipping temperature will be verified for each shipment in
          accordance with the Specifications.

          Precision will provide Omrix with a test certification for each lot of
          Cryoprecipitate shipped, which will be agreed by both parties. Such
          certification, an example of which is included with the
          Specifications, will specify the tests performed and values or results
          obtained. Talecris agrees to inform Omrix in writing of any change in
          the manufacturing process that may affect Talecris' ability to supply
          Cryoprecipitate in accordance with the Specifications.

          Talecris represents and warrants that the Cryoprecipitate provided to
          Omrix hereunder is not adulterated or misbranded within the meaning of
          the Federal Food, Drug, and Cosmetic Act.

          Omrix shall be responsible for ensuring that any Products derived from
          Cryoprecipitate meets the applicable specifications and regulations of
          the country in which such Product is distributed.

4.   DURATION

          This Agreement shall apply to all Cryoprecipitate from the process
          used by Precision shipped in bulk quantities to Omrix. This Agreement
          will be reviewed annually and updated as needed.

5.   WARNING

          Cryoprecipitate shall be prepared from large pools of human plasma.
          Products made from human plasma may contain infectious agents, such as
          viruses, that can cause disease. Talecris represents and warrants that
          the plasma of each donor used to manufacture Cryoprecipitate has been
          screened and found negative for markers indicating prior exposure to
          certain viruses, and for the presence of certain current virus
          infections. Plasma pools have been screened and certain viruses are
          inactivated and/or removed during the manufacturing process. Despite
          these measures, such products can still potentially transmit disease.
          There is also the possibility that unknown infectious agents may be
          present in such products. Appropriate care should be used in handling
          this material.

6.   ADDITIONAL PROVISIONS

          Cryoprecipitate purchased under this Agreement is for export from the
          US only. Cryoprecipitate may not be returned to the US nor may any
          product derived from Cryoprecipitate be returned to the US unless the
          Cryoprecipitate was used as a raw material for FDA licensed Products
          or Products under a current IND. Omrix clearly understands that no
          Precision and/or Talecris US
<PAGE>

Precision Pharma Servises, Talecris Biotherapeutics, Inc.            Page 4 of 4
and Omrix Biopharmaceuticals Ltd.
Manufacturing Agreement (Cryoprecipitate)

     license number or any other reference to Precision and/or Talecris may
     appear on the labeling of final product.

     Omrix shall be responsible for the export of Cryoprecipitate as a partially
     processed biological product for further manufacture and shall comply with
     all applicable FDA laws and regulations.

     Cryoprecipitate is for further manufacture use only and is not to be
     represented as suitable for use as a finished human drug.

     No additional testing for human pathogens outside of the testing agreed
     upon in the agreements may be performed on the Cryoprecipitate, any
     derivatives there from, or in-process samples, or resulting final
     containers without prior written approval of Talecris.

     Talecris will provide Regulatory documents consistent with Section 6.3 of
     the Supply Agreement.

     All requests for retrospective information, additional testing or samples
     outside of what is agreed upon in the agreements and specifications will be
     negotiated separately and will be in accordance with applicable regulations
     for partially processed biological products.

IN WITNESS THEREOF, the parties thereto have caused this Agreement to be
executed by their duly authorized representatives.

PRECISION PHARMA SERVICES                  OMRIX BIOPHARMACEUTICALS LTD.

By /s/ Allen D. Williams                   By /s/ Robert Taub
   -------------------------------------      ----------------------------------
   Allen Williams                          Name/Title
   Dir. Regulatory Affairs & QA
                                           Robert Taub
                                           Print Name/Title

Date 09/08/2006                            Date 09/27/2006

TALECRIS BIOTHERAPEUTICS, INC.

By /s/ Mary Ann Lamb
   -------------------------------------
   Mary Ann Lamb, Ph.D.
   Vice President, Regulatory Affairs

Date 09/16/2006

(SEAL)
<PAGE>

<TABLE>
<S>                               <C>                                                      <C>
(TALECRIS BIOTHERAPEUTICS LOGO)                STANDARD OPERATING PROCEDURE                SOP #: CS-000-AD-218
                                                                                           REVISION: 04
                                  TITLE: Preparation Of Manufacturing Agreements For The   PAGE 1 of 1
                                         Purchase And Sale Of Plasma Intermediates         ATTACHMENT 2
</TABLE>

                   INTERMEDIATE PRODUCT SPECIFICATION APPROVAL

Supercedes: N/A

The attached specifications for Cryoprecipitate that is purchased from Talecris
                                ---------------                        --------
                                  Intermediate                          Seller
by Omrix have been found acceptable.
   -----
   Buyer

These specifications will be effective:                   11 Sept. 2006.
                                                       ---------------------
                                                               Date

The revision number of these specifications will be:           NEW.
                                                       ---------------------

Associated Change Control Number:                              (1).
                                                       ---------------------
                                                       N/A if not applicable

Talecris SAP Number: (1)

Talecris Biotherapeutics, Inc. approval:   Omrix approval:

/s/ Anne Davis                             Refer to attached EAD 9-5-06
----------------------------------------   -------------------------------------
Date: 8-21-06                              Date:
Sr. Contract Manager                             -------------------------------
                                           Title:
                                                  ------------------------------

/s/ Amy W. Durham                          N/A EAD 9-11-06
----------------------------------------   -------------------------------------
Date: 8-30-06                              Date:
QO Manager                                       -------------------------------
                                           Title:
                                                  ------------------------------

Comments: (1) A Change Control will be initiated at Talecris to create a SAP
number for traceability of material sold to Omrix. This CCR must be closed prior
to first shipment. EAD 8-21-06.

<PAGE>

<TABLE>
<S>                               <C>                                                      <C>
(TALECRIS BIOTHERAPEUTICS LOGO)                STANDARD OPERATING PROCEDURE                SOP #: CS-000-AD-218
                                                                                           REVISION: 04
                                  TITLE: Preparation Of Manufacturing Agreements For The   PAGE 1 of 1
                                         Purchase And Sale Of Plasma Intermediates         ATTACHMENT 2
</TABLE>

                   INTERMEDIATE PRODUCT SPECIFICATION APPROVAL

Supercedes: N/A

The attached specifications for Cryoprecipitate that is purchased from Talecris
                                ---------------                        --------
                                  Intermediate                          Seller
by Omrix have been found acceptable.
   -----
   Buyer

These specifications will be effective:                                     .
                                                       ---------------------
                                                               Date

The revision number of these specifications will be:            NEW.
                                                       ---------------------

Associated Change Control Number:                               (1).
                                                       ---------------------
                                                       N/A if not applicable

Talecris SAP Number: (1)

Talecris Biotherapeutics, Inc. approval:   Omrix approval:

/s/ Anne Davis                             /s/ Karin Baer
----------------------------------------   -------------------------------------
Date: 8-21-06                              Date: Sept. 3, 2006
      Sr. Contract Manager                 Title: Director QA

/s/ Amy W. Durham
----------------------------------------   -------------------------------------
Date: 8-30-06                              Date:
      QO Manager                                 -------------------------------
                                           Title:
                                                  ------------------------------

Comments: (1) A Change Control will be initiated at Talecris to create a SAP
number for traceability of material sold to Omrix. This CCR must be closed prior
to first shipment. EAD 8-21-06.

<PAGE>

                            CRYOPRECIPITATE ("CRYO")
                         SPECIFICATIONS AND REQUIREMENTS
<TABLE>
<S>                             <C>              <C>                      <C>

/s/ Amy W. Durham               Aug. 30, 2006    Refer to attached.       EAD 9-5-06
-----------------------------   --------------   ----------------------   ----------
Talecris Quality Manager        Date             Omrix Quality Director   Date

/s/ Allen D. William            09/08/2006
-----------------------------   ----------
Precision Pharma Services,      Date
Director, Regulatory Affairs
and Quality Assurance
</TABLE>

Revision: NEW                                    Date Effective: 11 Sept. 2006

     1.   PURPOSE

          To provide specifications for Cryo manufactured by the Precision
          Pharma Services Inc USA on behalf of and from plasma provided by
          Talecris Biotherapeutics, Inc USA, to assure that the starting raw
          material (Human Normal Source Plasma) and the manufactured material
          (Cryo) meets specifications and established guidelines and standards.

     2.   REFERENCES

          U.S. Code of Federal Regulations 21 CFR part 640 (appropriate
          sections).

     3.   PLASMA REQUIREMENTS

          The Cryo must be manufactured from Human Normal Source Plasma meeting
          all current FDA requirements, including testing and screening
          requirements. Source Plasma donations can only be accepted from
          regular, repeat (Qualified) donors. Anti D reclassified Plasma is not
          acceptable.

          3.1  Human Normal Source Plasma for the manufacturing of Cryo must be
               harvested from FDA licensed and approved collection centers,
               currently certified under the Plasma Protein Therapeutics
               Association's (PPTA)

               The Centers and all associated testing laboratories (including
               Talecris' NAT test lab) have received the Clinical Laboratory
               Inspection Act (CLIA) licensure and approval.

          3.2  Donor selection as well as collection, production, quality
               control and storage of plasma are in compliance with the current
               WHO and FDA regulations and standards. No plasma is collected
               from high risks populations; epidemiological data is available
               for each collection center. The information will be provided on
               an annual basis as part of the plasma master file.

          3.3  The anticoagulant and container quality is in compliance with the
               FDA requirements.

          3.4  The Plasma used for the Cryo production must be less than three
               (3) years from date of donation.

          3.5  The plasma once collected must be frozen rapidly at not warmer
               than -20 degrees C, within one (1) hour and maintained at or
               below minus

                                   Page 1 of 7

<PAGE>

                            CRYOPRECIPITATE ("CRYO")
                         SPECIFICATIONS AND REQUIREMENTS

<TABLE>
<S>                             <C>              <C>                      <C>

/s/ Amy W. Durham               Aug. 30, 2006    /s/ Karin Baer           Sept. 3, 2006
-----------------------------   --------------   ----------------------   -------------
Talecris Quality Manager        Date             Omrix Quality Director   Date

-----------------------------   --------------
Precision Pharma Services,      Date
Director, Regulatory Affairs
and Quality Assurance
</TABLE>

Revision: NEW                                      Date Effective: _____________

     1.   PURPOSE

          To provide specifications for Cryo manufactured by the Precision
          Pharma Services Inc USA on behalf of and from plasma provided by
          Talecris Biotherapeutics, Inc USA, to assure that the starting raw
          material (Human Normal Source Plasma) and the manufactured material
          (Cryo) meets specifications and established guidelines and standards.

     2.   REFERENCES

          U.S. Code of Federal Regulations 21 CFR part 640 (appropriate
          sections).

     3.   PLASMA REQUIREMENTS

          The Cryo must be manufactured from Human Normal Source Plasma meeting
          all current FDA requirements, including testing and screening
          requirements. Source Plasma donations can only be accepted from
          regular, repeat (Qualified) donors. Anti D reclassified Plasma is not
          acceptable.

          3.1  Human Normal Source Plasma for the manufacturing of Cryo must be
               harvested from FDA licensed and approved collection centers,
               currently certified under the Plasma Protein Therapeutics
               Association's (PPTA).

               The Centers and all associated testing laboratories (including
               Talecris' NAT test lab) have received the Clinical Laboratory
               Inspection Act (CLIA) licensure and approval.

          3.2  Donor selection as well as collection, production, quality
               control and storage of plasma are in compliance with the current
               WHO and FDA regulations and standards. No plasma is collected
               from high risks populations; epidemiological data is available
               for each collection center. The information will be provided on
               an annual basis as part of the plasma master file.

          3.3  The anticoagulant and container quality is in compliance with the
               FDA requirements.

          3.4  The Plasma used for the Cryo production must be less than three
               (3) years from date of donation.

          3.5  The plasma once collected must be frozen rapidly at not warmer
               than -20 degrees C, within one (1) hour and maintained at or
               below minus

                                   Page 1 of 7

<PAGE>

               20 degrees C (-20 degrees C) during storage and transportation
               according to current CFR regulations.

          3.6  A certification for each Cryo shipment will be provided,
               indicating that the plasma was stored and shipped at a
               temperature at or below minus 20 degrees C. (-20 degrees C).

          3.7  Testing Required for each Unit of Plasma

               3.7.1 Each unit of plasma used for manufacture of the Cryo must
                    be tested and found non-reactive for: hepatitis B surface
                    antigen (HBsAg), antibodies to human immunodeficiency virus
                    types 1 and 2 (anti-HIV I/II), antibody to hepatitis C virus
                    (anti-HCV) by current generation FDA-approved test methods.
                    Additionally, once every four months the plasma donors are
                    tested for Syphilis and found to be negative.

               3.7.2 Each plasma unit must be NAT/PCR tested and found negative
                    for HAV, HBV, HIV-1, HCV and non-elevated for Parvo B19.

               Test Requirements for each unit:

<TABLE>
<CAPTION>
      TEST TYPE                         Test Requirements
      ---------                         -----------------
<S>                     <C>
HBsAg (1)               Non-Reactive (2)
Anti-HIV 1/2 (1)        Non-Reactive (2)
Anti-HCV (1)            Non-Reactive (2)
Syphilis (3)            Negative or Non-reactive for donor (test performed
                        on donor initially and every four (4) months)
Atypical Antibody (6)   Negative for donor (initial donation)
HIV-1 NAT (1)           Not Implicated (4)
HAV NAT (5)             Not Implicated (4)
HBV NAT (1)             Not Implicated (4)
HCV NAT (1)             Not Implicated (4)
Parvo B19 NAT (5)       Non-Elevated
</TABLE>

Notes:

(1.) Current generation, FDA approved test method must be used.

(2.) Some manufacturer's package inserts use the term "negative" and
     "non-reactive" interchangeably.

(3.) FDA approved syphilis test.

(4.) Some manufacturer's package inserts use the term "negative" and
     "not-implicated" interchangeably.

(5.) Currently not FDA approved test method. Upon approval, FDA approved methods
     must be used.

(6.) Test reagents for atypical antibody screening tests must minimally include
     specific anti-D antibody.

          3.8  Testing required for Plasma Pool

               3.8.1 The plasma pool used for manufacture of the cryoprecipitate
                    must be tested and found non-reactive for HBsAg, anti-HIV
                    I/II and HIV-1,

                                   Page 2 of 7
<PAGE>

                         HBV, HAV and HCV- RNA by PCR/NAT. The plasma pool must
                         be tested and found non-elevated for Parvo B19.

                    3.8.2 Talecris will test each Plasma Pool to ensure the
                         following quality limits (Omrix limits) are met:

               PLASMA POOL QUALITY LIMITS:

<TABLE>
<CAPTION>
TEST TYPE              Test Requirements
---------       ------------------------------
<S>             <C>
HBsAg           Non-reactive
Anti HIV-1/2    Negative
Anti-D          Non-Detectable (<1:1)
HPV-1 NAT       Negative
HAV NAT         Negative
HBV NAT         Negative
HCV NAT         Negative
Parvo B19 NAT   Non-Elevated (< or = 1 x 10(5)
                IU/mL)
</TABLE>

                    3.8.3 Omrix will test each Plasma Pool to ensure Omrix
                         internal specifications are met prior to authorizing
                         shipment of specific batches. Omrix will perform the
                         following tests.

               PLASMA POOL:

                                   TEST TYPE

                            Protein (Biuret)
                            TVC

     3.9  Representative pre-delivery samples (3 x 10 mL) of the Manufacturing
          Pool associated with each batch of Cryoprecipitate offered for sale to
          Omrix will be supplied to Omrix for evaluation.

          Based on the plasma pool certification and results of testing by
          Talecris/Precision and Omrix, Omrix will approve the shipment no later
          than 30 days after receipt of samples.

     3.10 The actual number of donors represented in the plasma pool from which
          an amount of approximately 20 kg of Cryo is derived does not exceed
          5700 donors.

4.   CRYO REQUIREMENTS

     4.1  The Cryo must be manufactured by Precision Pharma Services Inc USA
          under the responsibility of Talecris Biotherapeutics, Inc. USA. The
          manufacturing process must be approved and licensed by the FDA.

     4.2  The Cryo batch size (derived from one plasma pool only) should be as
          big as possible, but not less than 10kg.

     4.3  The Cryo to be sent to Omrix must be less than 6 months old from
          production date.

                                   Page 3 of 7

<PAGE>

     4.4  The storage and shipping temperature of Cryo must be minus 20 degrees
          C (-20 degrees C) or colder.

     4.5  Cryo must meet the Material specifications as detailed by Precision
          Pharma Services Inc USA under the responsibility of Talecris
          Biotherapeutics, Inc. USA and which are to be provided to Omrix.

     4.6  Representative pre-delivery samples (5 x l0gr) of each batch of Cryo
          (prior to freezing) will be supplied to Omrix to be tested by Omrix
          prior to purchasing Cyro for further manufacturing in a Fibrin Sealant
          product. Precision Pharma Services will release individual batches of
          Cyro based on their FDA BLA requirements. Omrix will authorize
          shipment of individual batches of Cryo based on the batch meeting the
          following quality limits (Omrix limits) after re-suspension and
          testing of the pre-delivery samples is performed at Omrix:

<TABLE>
<CAPTION>
PARAMETERS               LIMITS
----------            ------------
<S>                   <C>
Total protein         30-60mg/ml
% Clottable Protein   > or = 60%
Fibrinogen            20-40mg/ml
Factor XIII           2-9IU/ml
Factor VIII           5-20IU/ml
Fibronectin           0.5-6.0
VWFAg                 15-40IU/ml
TVC                   <3000 CFU/mL
</TABLE>

          Based on Cryo sample results tested by Omrix, and Plasma Pool results
          (tested by Talecris/Omrix), Omrix will approve the shipment of the
          Ciyo batch no later than 30 days after receipt of samples.

5.   GENERAL REQUIREMENTS:

     5.1  The following Plasma supplier information must be maintained for each
          center currently supplying plasma to Talecris by the Quality
          Organization at Talecris.

          1.   FDA approved ELA, PLA or BLA

          2.   CLIA registration certificate for the facility

          3.   Individual state licenses, as required

          4.   iQPP certification for the collection facility

          5.   FDA approved SOP manual

          6.   Viral Marker Rates - provided no less than quarterly

          7.   US FDA Form 483, inspection observations and follow-up/corrective
               actions

          8.   Talecris Quality Compliance Audits - conducted on a periodic
               basis, not less than once every 24 months.

     5.2  U.S. Plasma Master File should be submitted once to Omrix and then
          when versions are updated or new versions are issued.

                                  Page 4 of 7

<PAGE>

          The Plasma Master File should include the following information:

          1.   A list of names and addresses of blood/plasma collection
               establishments including any subcontractors and any separate
               sites for testing of individual donations.

               NOTE: The Plasma Master File is updated on an annual basis. The
               list of centers currently supplying plasma to Talecris is
               maintained by Talecris' Quality Organization.

          2.   Conditions of storage and transportation of the plasma

          3.   Epidemiological data on blood transmissible infections.

          4.   Selection/Exclusion Criteria

          5.   Donation traceability

          6.   Suitability of donors

          7.   Donor record system

          8.   Test result Management for laboratory results

          9.   Donor frequency and volume.

          10.  Screening of donations

               List of all tests performed (including NAT testing) on individual
               donations, minipools and plasma pools (if relevant), the test
               method, brand name of test kit, manufacturer, generation of test,
               license number and countries where licensed, plus validation of
               screening test methods.

          11.  Donor registration and applicant donor system

          12.  Donor deferral system

          13.  Look back procedures.

          14.  Post collection information system.

          15.  Batch numbering system

          16.  Information on the containers used for collection and of the
               anticoagulant solution.

          17.  Confirmation that all preventive measures are taken to reduce the
               possible risk of transmission of Creutzfeldt -Jacob disease (CJD)
               and variant Creutzfeldt -Jacob disease (vCJD) in blood and blood
               products.

     5.3  Any changes to the test kits used for the plasma testing must be
          notified in writing to Omrix at least 60 days prior to the shipment of
          any plasma using such changed test kits. Documentation on the test
          kits validation must be provided.

     5.4  A full description of the process for Cryo production must be provided
          to Omrix.

     5.5  Precision Pharma must receive written approval prior to shipment of a
          Cyro batch to Omrix.

     5.6  Manufacturing records for the production of Cryo including
          traceability to the individual plasma units will be kept on file per
          all FDA regulations.

          Manufacturing records and Bleeding lists (electronic data/hard copy)
          for each plasma pool are available for inspection by Omrix upon
          request.

     5.7  Consistent with Section 6.2 of the Supply Agreement, Omrix has the
          right to inspect/audit relevant areas of the facilities and the
          relevant documentation associated with the supply of plasma and for
          the

                                   Page 5 of 7
<PAGE>

          manufacturing of Cryo typically once per year This rate may be
          adjusted whenever considered necessary. Omrix will notify Talecris and
          Precision Pharma three weeks prior to the proposed audit. Talecris
          will notify Omrix if the audit date is acceptable. If the audit date
          is not acceptable an alternate date will be provided.
          Talecris/Precision and Omrix will use commercially reasonable efforts
          to accommodate the audit date.

     5.8  Talecris Biotherapeutics Inc./Precision Pharma must inform Omrix about
          each change in the Manufacturing Process affecting any Key Process
          Parameters as defined in Exhibit D of the Supply Agreement that
          requires FDA prior approval. Notification must be made to Omrix at
          least six (6) months prior to implementation. This allows time for
          Omrix to evaluate the impact of the change to the product being
          processed by Omrix. Omrix may not accept batches of Cryo if they will
          not comply with the approved requirements and specifications.

6.   STORAGE AND SHIPPING REQUIREMENTS

     6.1  Packaging - The cryoprecipitate from a single batch must be frozen in
          separate entities weighing < or = 5 kg. These separate entities will
          be grouped into shipments of NMT 25 kg. Each shipment will be double
          bagged using two plastic liners. Cryoprecipitate will be shipped in
          plastic sealable containers. Each container is to be labeled inside
          and outside.

     6.2  Storage and Shipping - Cryoprecipitate must be stored at -20 degrees C
          or colder and shipped upon request to Omrix. Cryoprecipitate must be
          shipped at -20 degrees C or colder. The temperature of each shipment
          must be monitored by Omrix. If temperature monitoring devices are
          required, Omrix will provide the devices and instructions on
          activation. Shipments from Precision to Omrix will be made Ex Works.

7.0  Certifications

     7.1  For each batch of Cryo shipped to Omrix, Precision Pharma/Talecris
          must submit the following documentation:

          1.   Proforma-Invoice (to be sent prior to shipment).

          2.   Certificate of Quality which will include the following data (to
               be sent prior to shipment):

               -    Tests and results performed on each contributing plasma unit
                    and all plasma pools

               -    A statement certificating that the Cryo is of the same
                    quality as required for the marketing and human use of
                    plasma derivatives products in USA and certificating that
                    the Cryo was processed by Precision Pharma Services Inc USA
                    current U.S. licenses approved by United States Food and
                    Drug Administration (FDA) regulations, including that there
                    were no manufacturing deviations or discrepancies for this
                    batch that could adversely affect the safety, purity, or
                    potency of the Cryo and that the Cryo has not been reworked
                    or reprocessed. Complete data indicating the initial

                                   Page 6 of 7

<PAGE>

                    plasma volume, calculated numbers of donors in the pool,
                    date of plasma pooling, oldest and recent donation date,
                    Plasma pool batch number, total amount of Cryo produced,
                    date of Cryo manufacture.

8.0  ATTACHMENTS

     8.1  Example - Cryoprecipitate Certification of Analysis

                                   Page 7 of 7

<PAGE>

             Attachment 1 - Example Certificate of Cryoprecipitate

                         PRECISION PHARMA SERVICES. INC.
                                 155 Duryea Road
                            Melville, New York 11747
                               Phone: 631-752-7314
                                Fax: 631-752-7354

                         Certificate of Cryoprecipitate
                                    For Omrix

Paste Batch #: __________________       Date of Manufacture: ___________________
Plasma Pool #: __________________       Plasma Volume: L
SAP#: ___________________________       Number of Pooled Units: ________________
Paste Weight: kg

This paste was fractionated from Precision plasma pool # XXXXXXX. The paste
contained only the material from Talecris shipment pool # XXXXXXX. All plasma
units processed in this pool were 100% inspected. No additional units were added
to the pre-selected pool except as authorized in writing by Talecris (Copy
attached) and noted on the Plasma Packing List.

The plasma units used in the manufacture of this batch of Paste are collected in
the United States in facilities licensed by the U.S. Food and Drug
Administration and inspected and approved by the FDA. These plasma units were
collected from healthy donors who met the criteria prescribed in 21 CFR, part
640.

All contributing plasma to this manufacturing pool has been tested and found
negative for HBsAg, anti-HIV-1/2, anti-HCV, HCV/HIV-1/HAV and HBV by NAT.
Donors, associated with these plasma units, were screened and found negative for
syphilis and undetectable for Anti-D. Additionally, the plasma units were
screened for parvovirus B19 by NAT and found non-elevated.

Oldest donation date: ______________
Most recent donation date: ______________

Manufacturing pool samples were tested by Talecris and found
negative/non-reactive for the following: HBsAg, Anti-D, HiV-1 & 2 Antibody, HCV/
HIV-1/HAV and HBV by NAT. Additionally, the manufacturing pool was tested for
parvovirus B19 by NAT and found non-elevated.

All lookback, positive, and other discrepant units were removed prior to
pooling.

This paste was processed in a manner minimizing microbial load and endotoxin
load.

The Cryoprecipitate batch has not been reworked for any reason.

The raw plasma was stored at -20 degrees C or less prior to Fractionation. The
intermediate stages were held at the required temperature ranges during the
process. Additionally, plasma was shipped from Talecris to Precision at
-20 degrees C or colder.

This paste was processed according to Precision procedures and BLA's and BLA
Amendments filed with and approved by CBER/FDA. The finished Cryoprecipitate was
held at -20 degrees C or colder prior to shipment.

Changes and/or variations in the process from those outlined on the production
records at Precision but with the constraints of the BLA and/or BLA Amendments
have been reviewed and approved by Precision and are appropriately documented in
the records. There were no significant deviations for this batch.

The Product Records for this batch are located at the Precision facility and are
available for further review by authorized personnel.

The plasma and the Paste are of the same quality as required for the marketing
and human use of plasma derivatives products in USA.

This batch was released by Precision Pharma Services, Inc.

I certify that the above information is correct.

-------------------------------------   ----------------------------------------
Quality Assurance                       Date<PAGE>
                                                                   EXHIBIT 10.38

                              EMPLOYMENT AGREEMENT

            EMPLOYMENT AGREEMENT (the "Agreement") dated as of August 28, 2006
by and between Omrix Biopharmaceuticals, Inc., a Delaware corporation (the
"Company") and Nanci I Prado (the "Executive").

            In consideration of the mutual covenants contained herein and other
good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:

1.    Term of Employment; Executive Representation.

a. Employment Term. Subject to the provisions of Section 6 of this Agreement,
Executive shall be employed by the Company for a period commencing on August 28,
2006 (the "Effective Date") and ending on the third anniversary of the Effective
Date (including any extensions thereof as detailed below, the "Employment Term")
on the terms and subject to the conditions set forth in the Agreement. Unless
earlier terminated in accordance with the terms hereof, on the third anniversary
of the Effective Date the Employment Term will be automatically extended for
successive one year terms, unless the Company or the Executive gives the other
party 90 days' prior written notice of an intention not to renew the agreement.

b. Executive Representation. Executive hereby represents to the Company that the
execution and delivery of this Agreement by Executive and the Company and the
performance by Executive of the Executive's duties hereunder shall not
constitute a breach of, or otherwise contravene, the terms of any employment
agreement or other agreement or policy to which Executive is a party or
otherwise bound.

2.    Position; Place of Performance.

a. During the Employment Term, Executive shall serve as Vice President, General
Counsel and Secretary of the Company. In such position, Executive shall have
such duties and authority commensurate with such position as shall be reasonably
assigned to her by the Chief Executive Officer ("CEO") and the Company's Board
of Directors and shall be given such executive and administrative powers and
authority as may be needed to carry out those duties. The Executive shall report
to the CEO. Executive's responsibilities will be those customary for the
position of Vice President, General Counsel and Secretary.

b. During the Employment Term, Executive shall devote Executive's full business
time and best efforts to the performance of Executive's duties hereunder and
will not engage in any other business, profession or occupation (including in an
advisory capacity, consulting capacity, or otherwise) for compensation or
otherwise which would conflict with the rendition of such services either
directly or indirectly, without the prior written consent of the CEO; provided
that

                                       1
<PAGE>

Executive shall be permitted to participate in such charitable and
community-related activities as Executive may choose; provided further that such
services do not interfere or conflict with her duties hereunder.

c. During the Employment Term, Executive shall be located in the Company's
offices in New York, New York, except for required travel on the Company's
business.

3.    Compensation.

a. During the Employment Term, the Company shall pay Executive a base salary
(the "Base Salary") at the annual rate of $210,000 (less applicable withholding
taxes), payable in regular installments in accordance with the Company's usual
payment practices but no less than monthly. Executive shall be entitled to such
increases in Executive's Base Salary, if any, as may be determined from time to
time in the sole discretion of the CEO and the Board.

b. With respect to each year during the Employment Term, provided the Executive
is employed and in good standing at the time bonuses are distributed, Executive
shall be eligible to receive an annual bonus award (an "Annual Bonus")
calculated based on Company and individual performance measures established by
the Board each year. During the Employment Term, the Executive's target annual
bonus award shall be 40% of her Base Salary and the Executive may receive
between 10% and her target percentage (pro-rated to reflect the partial year of
employment), based on the level of achievement of such performance measures as
determined in the sole discretion of the CEO, as approved by the Compensation
Committee.

c. During the Term of the Executive's employment hereunder, the Executive shall
be eligible to participate in the Company's 2006 Equity Incentive Plan or its
successor plan (the "Equity Incentive Plan") in accordance with the terms and
conditions of the Equity Incentive Plan. Except as set forth in paragraph 3(d)
below, the decision to grant any award to the Executive pursuant to the Equity
Incentive Plan, and the amount of any such award, shall be within the sole
discretion of the Company's Board of Directors.

d. The Company shall cause the Executive to be granted stock options to purchase
36,000 shares of Company common stock pursuant to the Equity Incentive Plan (the
"Stock Options") as soon as practicable following the Effective Date. The
exercise price of the Stock Options shall be the fair market value of the Stock
Options on the date of grant, and the Stock Options shall vest over four years,
with 9,000 Stock Options vesting each year based on continued employment
(subject to acceleration upon a Change in Control, as set forth in paragraph
6(c)(iii) herein below). The complete terms and condition of the Stock Options
shall be set forth in a separate stock option agreement between the Executive
and the Company.

4. Business Expenses. During the Employment Term, reasonable, documented
business travel expenses and other business expenses incurred by Executive in
the performance of Executive's duties hereunder shall be reimbursed by the
Company in accordance with Company policies, including without limitation,
documented expenses up to a total aggregate of US$3,500 incurred by Executive in
connection with complying with mandatory continuing legal credit courses per
year and bar association dues for the states of New York and California.

                                       2
<PAGE>

5. Benefits; Vacation. The Company does not currently maintain any employee
benefits plans, and has agreed to pay directly, or reimburse the Executive, for
the Executive's actual, documented costs in connection with: (i) establishing
and maintaining a 401(k) plan or other comparable deferred tax savings plan for
the benefit of the Executive, up to a maximum of $1,000 a year; and (ii)
purchasing health insurance coverage if the Executive is not otherwise entitled
to health insurance coverage through her spouse's employer. If such health
insurance coverage is obtained by the Company for the Executive, the cost of
such coverage will be reduced from the Base Salary paid to Executive. The
Executive shall be solely responsible for any income tax liability resulting
from this Company payments or reimbursements. During the first year of the
Employment Term, the Executive shall be entitled to fifteen (15) paid vacation
days per calendar year, which amount shall be pro-rated for any partial calendar
year during which the Executive is employed by the Company and eighteen (18)
paid vacation days for each subsequent calendar year of the Employment Term.
Executive shall accrue such vacation days in accordance with the policies of the
Company as in effect from time to time. Executive shall also be entitled to all
U.S. Federal holidays. The Company shall provide Executive with the right to
participate in and to receive benefits from accident, disability, medical,
pension, bonus, stock, profit-sharing and savings plans and similar benefits
made available to all employees of the Company located in the United States or
all other Company executives as such plans and benefits may be adopted by the
Company.

6. Termination. The Employment Term and Executive's employment hereunder may be
terminated by either party at any time and for any reason; provided that
Executive and the Company will be required to give the other party hereto at
least 30 days advance written notice of any resignation or termination, as the
case may be of Executive's employment. Notwithstanding any other provision of
this Agreement, the provisions of this Section 6 shall exclusively govern
Executive's rights upon termination of employment with the Company and its
affiliates.

a. By the Company For Cause; By Executive for any Reason (other than Good
Reason); Expiration of the Employment Term.

      (i) The Employment Term and Executive's employment hereunder may be
      terminated by the Company for Cause (as defined below) or by the Executive
      for any reason (other than Good Reason (as defined below)), subject to the
      notice period required by this Section 6.

For purposes of this Agreement, "Cause" shall mean: (i) the habitual,
intentional or willful failure of by the Executive to render services to the
Company in accordance with her reasonably assigned duties and responsibilities
under this Agreement (other than any such failure resulting from the Executive's
Disability); (ii) willful misconduct or gross negligence of the Executive in the
performance of her duties and reasonably assigned responsibilities for the
Company or any of its subsidiaries or affiliates under this Agreement; (iii) the
Executive's conviction of, or plea of guilty or nolo contendre to, a felony,
whether or not committed in the course of performing her duties for the Company
or any of its subsidiaries or affiliates; (iv) the Executive's disloyalty,
deliberate dishonesty, breach of fiduciary duty or material breach of the terms
of this Agreement; (v) the commission by the Executive of embezzlement, theft or
any other fraudulent act or omission; (vi) the commission by the Executive of
any act or omission in violation of the

                                       3
<PAGE>

reasonable rules or policies of the Company that results in material loss,
damage or injury to the Company or any of its subsidiaries or affiliates or
materially adversely affects the business activities, reputation, goodwill or
image of the Company or any of its subsidiaries or affiliates; (vii) the
unauthorized disclosure by the Executive of any "Confidential Information," as
that term is defined in the Undertaking or any other breach of the Undertaking
(defined below) other than as is reasonably believed to comply with lawful legal
or administrative process; (viii) the commission by the Executive of any act
that constitutes unfair competition with the Company or any of its subsidiaries
or affiliates; (ix) the material breach by the Executive of any agreement to
which she and the Company or any of its subsidiaries or affiliates are parties
that results in material loss, damage or injury to the Company or any of its
subsidiaries or affiliates, or materially adversely affects the business
activities, reputation, goodwill or image of the Company or any of its
subsidiaries or affiliates; provided, that in the event of (i) above, the
Company shall provide written notice to Executive describing the nature of such
event and Executive shall thereafter have thirty (30) business days to cure such
event.

      (ii) If Executive's employment is terminated by the Company for Cause, or
      if Executive terminates her employment hereunder for any reason other than
      Good Reason (as defined below), Executive shall be entitled to receive the
      following amounts (collectively, the "Accrued Obligations"):

      (A) the Base Salary through the date of termination;

      (B) any Annual Bonus earned but unpaid as of the date of termination for
      any previously completed full calendar year;

      (C) any vacation days earned but unpaid as of the termination date for
      previously completed calendar year;

      (D) any vacation days earned but not taken; and

      (E) reimbursement for any unreimbursed business expenses properly incurred
      by Executive in accordance with Company policy prior to the date of
      Executive's termination.

            In addition, if the Employment Term and Executive's employment under
      this Agreement is terminated by reason of the expiration of the Employment
      Term following a notice of non-renewal by the Company or Executive,
      Executive shall be entitled to receive the Accrued Obligations.

            Following such termination of Executive's employment by the Company
      for Cause, by Executive for any reason other than Good Reason (as defined
      below), or by reason of the expiration of the Employment Term, except as
      set forth in this Section 6(a), Executive shall have no further rights to
      any compensation or any other benefits under this Agreement.

            b.    Good Reason. Executive shall have the right to terminate this
                  Agreement for Good Reason. Good Reason shall mean: (A) the
                  failure to elect or reelect the Executive to the position of
                  Vice

                                       4
<PAGE>

                  President, General Counsel or the removal of the Executive
                  from such position (other than due to a termination of her
                  employment at the end of the Employment Term by a 90 days
                  notice as stipulated in section 1. a above, a termination for
                  Cause, without Cause, or as a result of Disability, death or
                  the Executive's resignation without Good Reason); (B) a change
                  in the reporting structure so that the Executive reports to a
                  person other than the Chief Executive Officer; (C) the
                  relocation of the offices of the Company at which Executive is
                  principally located (other than a relocation within the
                  Borough of Manhattan, or the Company's requiring the Executive
                  to be based anywhere other than such offices; (D) any breach
                  by the Company of its obligations under this Agreement if not
                  remedied after 30 days' written notice from the Executive; or
                  (E) in connection with a Change in Control, the occurrence,
                  without the Executive's written consent, of (i) the assignment
                  to the Executive of duties inconsistent in any material
                  respect with the Executive's position (including status,
                  offices, the title of Vice President, General Counsel of the
                  Company and reporting requirements), authority or
                  responsibilities in effect immediately prior to the planning,
                  announcement or effective date of such Change of Control or a
                  material diminution in such position, authority or
                  responsibilities; (ii) a reduction in the Executive's
                  aggregate compensation (base salary, target annual bonus award
                  and/or long-term and short-term cash incentive compensation)
                  or aggregate benefits as in effect immediately prior to the
                  planning, announcement or effective date of such Change of
                  Control; (iii) the failure by the Company to (x) continue in
                  effect any material compensation or benefit plan or program
                  (including without limitation any life insurance, medical,
                  health, dental and accident or disability plan and any
                  vacation or automobile program or policy) in which the
                  Executive participates immediately prior to such Change of
                  Control, or continue the Executive's participation therein (or
                  in such substitute or alternative plan) on a basis not
                  materially less favorable than the basis existing immediately
                  prior to the Change of Control; (iv) the relocation of the
                  offices of the Company at which Executive is principally
                  located (other than a relocation within the Borough of
                  Manhattan, or the Company's requiring the Executive to be
                  based anywhere other than such offices, except for required
                  travel on the Company's business to an extent substantially
                  consistent with the Executive's business travel obligations
                  prior to the Change of Control; or (v) the failure of the
                  Company to obtain the agreement from any successor to the
                  Company to assume and agree to perform this Agreement.

      b.    Disability or Death.

                                       5
<PAGE>

The Employment Term and Executive's employment hereunder shall terminate upon
Executive's death or if Executive becomes physically or mentally incapacitated
and is therefore unable for a period of six (6) months during any twelve (12)
month period to perform Executive's duties, determined by the Company in its
reasonable discretion (such incapacity hereinafter referred to as "Disability").
Upon termination of Executive's employment hereunder for either Disability or
death, Executive or Executive's estate (as the case may be) shall be entitled to
receive the Accrued Obligations plus any Company death or disability policy or
plan benefits, as may be in effect from time to time, for such circumstances.

      (i) Following Executive's termination of employment due to death or
      Disability, except as set forth in this Section 6(b), Executive or
      Executive's estate (as the case may be) shall have no further rights to
      any compensation or any other benefits under this Agreement.

c.    By the Company Without Cause.

      (i) The Employment Term and Executive's employment hereunder may be
      terminated by the Company without Cause.

      (ii) If Executive's employment is terminated by the Company without Cause
      (other than by reason of death or Disability) or by Executive for Good
      Reason, and, in each case, not on or following a Change in Control (as
      defined below), Executive shall be entitled to receive:

      (A) the Accrued Obligations; and

      (B) continuation of the Executive's then-current Base Salary for three
      months.

      (iii) If Executive's employment is terminated by the Company (or its
      successor) without Cause (other than by reason of death or Disability) or
      by the Executive for Good Reason, in each case, on or following a Change
      in Control (as defined below), Executive shall be entitled to receive:

      (A) the Accrued Obligations;

      (B) continuation of the Executive's then-current base salary for six
      months, payable in one lump sum no later than 30 days following such
      termination date; and

      (C) all options granted to the Executive shall become immediately
      accelerated and fully exercisable.

            Following Executive's termination of employment by the Company
      without Cause (other than by reason of Executive's death or Disability) or
      by the Executive for Good Reason),, except as set forth in this Section
      6(c), Executive shall have no further rights to any compensation or any
      other benefits under this Agreement. Notwithstanding the foregoing, the
      Company's obligation to provide the Executive the payments described in

                                       6
<PAGE>

      this Section 6(c) shall be contingent upon Executive's continued
      compliance with the restrictive covenants set forth in Section 7.

      (iv) For purposes of this Agreement, "Change in Control" shall mean the
      first to occur of any of the following:

      (A) any "person," as such term is used in Sections 13(d) and 14(d) of the
      Exchange Act (other than (A) the Company, (B) any trustee or other
      fiduciary holding securities under an employee benefit plan of the
      Company, and (C) any corporation owned, directly or indirectly, by the
      stockholders of the Company in substantially the same proportions as their
      ownership of Stock), is or becomes the "beneficial owner" (as defined in
      Rule 13d-3 under the Exchange Act), directly or indirectly, of securities
      of the Company representing 51% or more of the combined voting power of
      the Company's then outstanding voting securities (excluding any person who
      becomes such a beneficial owner in connection with a transaction
      immediately following which the individuals who comprise the Board
      immediately prior thereto constitute at least a majority of the Board, the
      entity surviving such transaction or, if the Company or the entity
      surviving the transaction is then a subsidiary, the ultimate parent
      thereof);

      (B) there is consummated a merger, reorganization, recapitalization,
      combination or statutory share exchange or similar transaction involving
      or consolidation of the Company or any direct or indirect subsidiary of
      the Company with any other corporation (a "Business Combination"), other
      than a Business Combination immediately following which the individuals
      who comprise the Board immediately prior thereto constitute at least a
      majority of the Board, the entity surviving such Business Combination or,
      if the Company or the entity surviving such merger is then a subsidiary,
      the ultimate parent thereof; or

      (C) the stockholders of the Company approve a plan of complete liquidation
      of the Company or there is consummated an agreement for the sale or
      disposition by the Company of all or substantially all of the Company's
      assets (or any transaction having a similar effect), other than a sale or
      disposition by the Company of all or substantially all of the Company's
      assets to an entity, immediately following which the individuals who
      comprise the Board immediately prior thereto constitute at least a
      majority of the board of directors of the entity to which such assets are
      sold or disposed of or, if such entity is a subsidiary, the ultimate
      parent thereof.

            Notwithstanding the foregoing, a Change in Control shall not be
      deemed to have occurred by virtue of (x) an public offering of securities
      of the Company by the Company or its security holders that is registered
      with the Securities and Exchange Commission not involving a Business
      Combination or (y) the consummation of any transaction or series

                                       7
<PAGE>

      of integrated transactions immediately following which the holders of the
      Stock immediately prior to such transaction or series of transactions
      continue to HAVE substantially the same proportionate ownership and voting
      rights in an entity which owns all or substantially all of the assets of
      the Company immediately following such transaction or series of
      transactions.

d. Notice of Termination. Any purported termination of employment by the Company
or by Executive (other than due to Executive's death) shall be communicated by
written Notice of Termination to the other party hereto in accordance with
Section 8(g) hereof. For purposes of this Agreement, a "Notice of Termination"
shall mean a notice which shall indicate the specific termination provision in
this Agreement relied upon and shall set forth in reasonable detail the facts
and circumstances claimed to provide a basis for termination of employment under
the provision so indicated.

7.    Confidentiality/Non-Competition.

a. The Executive has executed a separate Employee Undertaking (the
"Undertaking"), pursuant to which she agrees to be bound by certain
confidentiality, non-competition, non-solicitation and other restrictive
covenants and which are incorporated herein by reference.

b. The Executive hereby agrees and covenants, in addition to the provisions of
the Undertaking, that she shall not, directly or indirectly, in any capacity
whatsoever, including, without limitation, as an employee, employer, consultant,
member, principal, partner, shareholder, officer, director, agent, holder of
financial interest, or any other individual or representative capacity, in any
individual, partnership, corporation, limited liability company, association,
trust, joint venture, unincorporated association or government entity
("Person"), whether on the Executive's own behalf or on behalf of any Person or
entity or otherwise howsoever (other than as a holder of not more than one
percent (1%) of the combined voting power of the outstanding stock of a publicly
held company), during the Executive's employment with the Company and for a
period of one (1) year following after the termination or cessation of this
Agreement and of the Executive's employment with the Company for any reason,
directly or indirectly engage in, own, manage, operate, control, be employed by,
consult for, participate in, or be connected in any manner with the ownership,
management, operation or control of any business in competition with the
"business of the Company or its affiliates or their successors The "business of
the Company or its affiliates or their successors" is defined as the business of
plasma fractionation or manufacturing, selling, researching, distributing,
marketing or otherwise conducting business in any way relating to the
development, manufacture, sale or distribution of plasma derivative products,
including, without limitation, biological surgical or fibrin adhesives or their
recombinant or monoclonal antibody analogs, whether the Company is actually
engaged in such business activities or has taken action to begin engaging in
such business activities, even if any related services or products are not
completed or ready for marketing or distribution, at the time that this
Agreement and the Executive's employment with the Company terminates.

c. The Executive acknowledges and recognizes the highly competitive nature of
the business of the Company, and agrees that the covenants set forth herein,
including the Undertaking, are reasonable and necessary to protect the Company's
interests. It is expressly understood and agreed that although Executive and the
Company consider such restrictions to be

                                       8

<PAGE>

reasonable, if a final judicial determination is made by a court of competent
jurisdiction that the time or territory or any other restriction contained
herein and in the Undertaking is an unenforceable restriction against Executive,
the provisions of this Agreement and the Undertaking shall not be rendered void
but shall be deemed amended to apply as to such maximum time and territory and
to such maximum extent as such court may judicially determine or indicate to be
enforceable. Alternatively, if any court of competent jurisdiction finds that
any restriction contained herein or in the Undertaking is unenforceable, and
such restriction cannot be amended so as to make it enforceable, such finding
shall not affect the enforceability of any of the other restrictions contained
therein.

8. Specific Performance. Executive acknowledges and agrees that the Company's
remedies at law for a breach or threatened breach of any of the provisions of
Section 7 would be inadequate and, in recognition of this fact, Executive agrees
that, in the event of such a breach or threatened breach, in addition to any
remedies at law, the Company, without posting any bond, shall be entitled to
cease making any payments or providing any benefit otherwise required by this
Agreement and obtain equitable relief in the form of specific performance,
temporary restraining order, temporary or permanent injunction or any other
equitable remedy which may then be available.

9. Indemnification. The Company will enter into an indemnification agreement
with Executive in the form adopted by the Company's board of directors as of the
date hereof.

10.   Miscellaneous.

a. Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware, without regard to conflicts
of laws principles thereof.

b. Entire Agreement/Amendments. This Agreement and the Undertaking contain the
entire understanding of the parties with respect to the subject matter hereof
and thereof and shall supersede any other agreements, offer terms or
representations, oral or otherwise, express or implied, with respect to the
subject matter hereof and thereof which have been made by either party. There
are no restrictions, agreements, promises, warranties, covenants or undertakings
between the parties with respect to the subject matter herein other than those
expressly set forth herein. This Agreement and the Undertaking may not be
altered, modified, or amended except by written instrument signed by the parties
hereto.

c. No Waiver. The failure of a party to insist upon strict adherence to any term
of this Agreement on any occasion shall not be considered a waiver of such
party's rights or deprive such party of the right thereafter to insist upon
strict adherence to that term or any other term of this Agreement.

d. Severability. In the event that any one or more of the provisions of this
Agreement and/or the Undertaking shall be or become invalid, illegal or
unenforceable in any respect, the validity, legality and enforceability of the
remaining provisions of this Agreement and/or the Undertaking shall not be
affected thereby.

11. Binding Agreement; Assignment. This Agreement shall inure to the benefit of
and be binding upon the personal or legal representatives, executors,
administrators, successors, heirs,

                                       9
<PAGE>

distributees, devisees and legatees of the Executive. This Agreement shall not
be assignable by Executive. This Agreement may be assigned by the Company to a
company which is a successor in interest to substantially all of the business
operations of the Company or to a parent of the Company. Such assignment shall
become effective when the Company notifies the Executive of such assignment or
at such later date as may be specified in such notice. Upon such assignment, the
rights and obligations of the Company hereunder shall become the rights and
obligations of such successor company, provided that any assignee expressly
assumes the obligations, rights and privileges of this Agreement and provided,
further, that such assignment shall not affect the Executive's right to
terminate for Good Reason, including upon a Change of Control.

a. Notice. For the purpose of this Agreement, notices and all other
communications provided for in the Agreement shall be in writing and shall be
deemed to have been duly given when delivered or mailed by United States
registered mail, return receipt requested, postage prepaid, addressed to the
respective addresses set forth below Agreement, or to such other address as
either party may have furnished to the other in writing in accordance herewith,
except that notice of change of address shall be effective only upon receipt.

If to the Company:

                  Omrix Biopharmaceuticals, Inc.
                  630 Fifth Avenue
                  New York, New York, 10111
                  Attn: C.E.O.

If to Executive:  To the most recent address of Executive set forth in the
                  personnel records of the Company.

b. Withholding Taxes. Any payments provided for hereunder shall be paid net of
any applicable withholding taxes required under federal, state or local law and
any additional withholding to which the Executive has agreed.

c. Survival. The obligations of the Company and the Executive under this
Agreement which by their nature may require performance after the expiration or
termination of the Employment Term (including, without limitation, those under
Section 7) shall survive the expiration or termination of this Agreement.

d. Counterparts. This Agreement may be signed in counterparts, each of which
shall be an original, with the same effect as if the signatures thereto and
hereto were upon the same instrument.

            IN WITNESS WHEREOF, the parties hereto have duly executed this
Agreement as of the day and year first above written.

                                       10
<PAGE>

                                      /s/ Nanci Prado
                                      ------------------------------------------
                                      Nanci Prado

                                      OMRIX BIOPHARMACEUTICALS, INC.

                                      By:      /s/ Robert Taub
                                               ---------------------------------
                                      Name:    Robert Taub
                                      Title:   Chief Executive Officer

                                       11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}]]